

=> d his

(FILE 'HCAPLUS' ENTERED AT 08:17:30 ON 12 MAY 2003)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 08:20:08 ON 12 MAY 2003
ACT PATEL2/A

L1 STR
L2 (541)SEA FILE=REGISTRY SSS FUL L1
L3 STR
L4 169 SEA FILE=REGISTRY SUB=L2 SSS FUL L3

L5 169 S L4 AND (CAPLUS OR CA)/LC
L6 126 S L4 AND USPATFULL/LC
L7 0 S L6 NOT L5

FILE 'HCAPLUS' ENTERED AT 08:20:41 ON 12 MAY 2003
L8 20 S L4

FILE 'HCAOLD' ENTERED AT 08:20:46 ON 12 MAY 2003
L9 0 S L4

=> fil-reg
FILE 'REGISTRY' ENTERED AT 08:21:50 ON 12 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAY 2003 HIGHEST RN 514167-89-6
DICTIONARY FILE UPDATES: 11 MAY 2003 HIGHEST RN 514167-89-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


=> d questat 14
'QUESTAT' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
ENTER DISPLAY FORMAT (IDE):end

=> d que stat 14
L1 STR
8 13 9 7
O OH G1 O
|| | ||| Ak @10 Ak-Cy
|| | ||| @11 12
H—C---N—CH2—CH—C
1 2 3 4 5 6 N
14

VAR G1=10/11
NODE ATTRIBUTES:
NSPEC IS RC AT 14
CONNECT IS E1 RC AT 10
CONNECT IS X2 RC AT 11
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L2 (541)SEA FILE=REGISTRY SSS FUL L1
L3 STR



Hy @19

VAR G1=10/11

VAR G2=15/19

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 10

CONNECT IS X2 RC AT 11

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 19

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

L4 169 SEA FILE=REGISTRY SUB=L2 SSS FUL L3

100.0% PROCESSED 541 ITERATIONS

169 ANSWERS

SEARCH TIME: 00.00.01

=> d his 15-17

(FILE 'REGISTRY' ENTERED AT 08:20:08 ON 12 MAY 2003)

L5 169 S L4 AND (CAPLUS OR CA)/LC
L6 126 S L4 AND USPATFULL/LC

L7 0 S L6 NOT L5

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 08:22:17 ON 12 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 May 2003 VOL 138 ISS 20
FILE LAST UPDATED: 11 May 2003 (20030511/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d que nos 18

```
L1      STR
L2 ( 541) SEA FILE=REGISTRY SSS FUL L1
L3      STR
L4      169 SEA FILE=REGISTRY SUB=L2 SSS FUL L3
L8      20 SEA FILE=HCAPLUS ABB=ON PLU=ON L4
```

=> d .ca hitstr 18 1-20

I8 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:23020 HCAPLUS
DOCUMENT NUMBER: 138:85604
TITLE: A crystallized catalytic domain of human matrix metalloproteinase 9 (MMP9) and the use of its three dimensional structure to design MMP9 modulators
INVENTOR(S): Jepson, Holly; Minshull, Claire; Paupert, Richard; Rowsell, Sian
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
SOURCE: PCT Int. Appl., 227 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002729	A1	20030109	WO 2002-SE1266	20020624
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: SE 2001-2298 A 20010627
AB The invention provides a crystal structure of a polypeptide corresponding to the catalytic domain of a human matrix metalloproteinase protein, MMP9, in complex with a reversible hydroxamate inhibitor. The active site binding region of the MMP9 protein is defined by its amino acid residues and their *at.* coordinates. This three dimensional structure may be used to select or design chem. modulators of MMP9, particularly MMP9 inhibitors. These modulators may be used to treat a metalloproteinase

mediated disease or condition.

IC ICM C12N009-50
ICS C12Q001-37; A61K038-48

CC 7-5 (Enzymes)
Section cross-reference(s): 1, 75


IT 146480-36-6DP, Matrix metalloproteinase 9, complexes with hydroxamate inhibitor **481701-43-3DP**, complexes with MMP9 catalytic domain
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystd. catalytic domain of wild-type and mutant human matrix metalloproteinase 9 (MMP9) and use of its three dimensional structure to design MMP9 modulators)

IT **481701-43-3DP**, complexes with MMP9 catalytic domain
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystd. catalytic domain of wild-type and mutant human matrix metalloproteinase 9 (MMP9) and use of its three dimensional structure to design MMP9 modulators)

RN 481701-43-3 HCAPLUS

CN L-Valinamide, (2R)-N-formyl-N-hydroxy-2-(2-methylpropyl)-.beta.-alanyl-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:977805 HCAPLUS
DOCUMENT NUMBER: 138:55864
TITLE: Preparation of N-hydroxyamide-substituted pyrrolidine derivatives as inhibitors of peptidyl deformylase
INVENTOR(S): Patel, Dinesh V.; Yuan, Zhengyu; Jain, Rakesh K.; Lewis, Jason G.; Jacobs, Jeffrey
PATENT ASSIGNEE(S): Versicor, Inc., USA; Novartis AG
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----


WO 2002102791 A1 20021227 WO 2002-EP6586 20020614
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU,
 LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG,
 SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, TR

US 2003069223 A1 20030410 US 2002-171705 20020614

PRIORITY APPLN. INFO.: US 2001-298418P P 20010615

OTHER SOURCE(S): MARPAT 138:55864

GI



AB Title compds. I [R1 = (hetero)aryl; R2 = H, halo, OH; R3 = H, halo, alkyl, heteroalkyl, etc.; X = CH₂, S; W = amino, alkyl; Y = COOH, SH, N(OH)CHO, CONHOH, etc.; n = 0-3; with provisions] are prep'd. For instance, (2R)-2-((5S)-2,2-dimethyl-4-oxo-1,3-dioxolan-5-yl)hexanoic acid (prep'n. given) was coupled to 2-(pyrrolidin-2-yl)pyridine to give diastereomers II. IC₅₀ of selected example compds. detd. for the zinc-contg. peptidyl deformylase (PDF) ranges from about 0.585 .mu.M to 0.004 .mu.M and for nickel-contg. PDF ranges from about 0.06 .mu.M to about 0.0001 .mu.M. I are useful for preventing contamination of a cell culture medium.

IC ICM C07D401-14

ICS C07D207-08; A61P031-04

CC 27-10 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 34, 63

IT 479067-13-5P 479067-14-6P 479067-15-7P, (2S,3R)-2-Hydroxy-3-[(2R)-2-[pyridin-3-yl]pyrrolidine-1-yl]carbonyl]heptanoic acid hydroxyamide
 479067-16-8P, (2S,3R)-2-Hydroxy-3-[(2S)-2-[pyridin-3-yl]pyrrolidine-1-yl]carbonyl]heptanoic acid hydroxyamide 479067-17-9P,
 (2S,3R)-2-Hydroxy-3-[(2R)-2-[pyridin-4-yl]pyrrolidine-1-yl]carbonyl]heptanoic acid hydroxyamide 479067-18-0P,
 (2S,3R)-2-Hydroxy-3-[(2S)-2-[pyridin-4-yl]pyrrolidine-1-yl]carbonyl]heptanoic acid hydroxyamide 479067-19-1P 479067-20-4P
 479067-21-5P 479067-22-6P 479067-23-7P, (2S,3R)-2-Hydroxy-3-[(2S)-2-(oxazol-2-yl)pyrrolidine-1-yl]carbonyl]heptanoic acid hydroxyamide
 479067-24-8P, (2S,3R)-2-Hydroxy-3-[(2S)-2-(5-methyloxazol-2-yl)pyrrolidine-1-yl]carbonyl]heptanoic acid hydroxyamide 479067-25-9P,
 (2R,3R)-2-Fluoro-3-[(2S)-2-(oxazol-2-yl)pyrrolidine-1-yl]carbonyl]heptanoic acid hydroxyamide 479067-26-0P,
 (2S,3R)-2-Fluoro-3-[(2S)-2-(oxazol-2-yl)pyrrolidine-1-yl]carbonyl]heptanoic acid hydroxyamide 479067-27-1P,
 N-Hydroxy-N-[(2R)-2-[(2S)-2-(oxazol-2-yl)pyrrolidine-1-yl]carbonyl]hexyl]formamide 479067-28-2P, N-Hydroxy-N-[(3R)-3-[(2R)-2-

(pyridin-2-yl)pyrrolidine-1-yl]carbonyl]hexyl]formamide 479067-29-3P,
 N-Hydroxy-N-[(3R)-3-[[[(2S)-2-(pyridin-2-yl)pyrrolidine-1-
 yl]carbonyl]hexyl]formamide 479067-30-6P, (2S,3R)-2-Hydroxy-3-[[[(2S)-2-
 (4,5-dimethylthiazol-2-yl)pyrrolidine-1-yl]carbonyl]heptanoic acid
 hydroxyamide 479067-31-7P, (2S,3R)-2-Hydroxy-3-[[[(2S)-2-(4-phenylthiazol-
 2-yl)pyrrolidine-1-yl]carbonyl]heptanoic acid hydroxyamide 479067-32-8P,
 (2S,3R)-2-Hydroxy-3-[[[(2S)-2-(4-methylthiazol-2-yl)pyrrolidine-1-
 yl]carbonyl]heptanoic acid hydroxyamide 479067-33-9P,
 (2S,3R)-2-Hydroxy-3-[[[(2S)-2-(benzimidazol-2-yl)pyrrolidine-1-
 yl]carbonyl]heptanoic acid hydroxyamide 479067-34-0P 479067-35-1P
 479067-36-2P, (2S,3R)-2-Hydroxy-3-[[[(2S)-2-(5-tert-butyloxazol-2-
 yl)pyrrolidine-1-yl]carbonyl]heptanoic acid hydroxyamide 479067-37-3P,
 (2S,3R)-2-Hydroxy-3-[[[(2S)-2-(5-phenyloxazol-2-yl)pyrrolidine-1-
 yl]carbonyl]heptanoic acid hydroxyamide 479067-38-4P,
 (2S,3R)-2-Hydroxy-3-[[[(2S)-2-(5-isobutyloxazol-2-yl)pyrrolidine-1-
 yl]carbonyl]heptanoic acid hydroxyamide 479067-39-5P,
 (2S,3R)-2-Hydroxy-3-[[[(2S)-2-(4,5-dimethyloxazol-2-yl)pyrrolidine-1-
 yl]carbonyl]heptanoic acid hydroxyamide 479067-40-8P,
 (2S,3R)-2-Hydroxy-3-[[[(2S)-2-(oxazol-2-yl)pyrrolidine-1-
 yl]carbonyl]heptanoic acid 479067-41-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of N-hydroxyamide-substituted pyrrolidine derivs. as inhibitors
 of peptidyl deformylase)

IT 479067-27-1P, N-Hydroxy-N-[(2R)-2-[[[(2S)-2-(oxazol-2-
 yl)pyrrolidine-1-yl]carbonyl]hexyl]formamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of N-hydroxyamide-substituted pyrrolidine derivs. as inhibitors
 of peptidyl deformylase)

RN 479067-27-1 HCAPLUS

CN Pyrrolidine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-2-(2-
 oxazolyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:977804 HCAPLUS
 DOCUMENT NUMBER: 138:55863

TITLE: Preparation of N-formyl-N-hydroxylamino-substituted pyrrolidine derivatives as inhibitors of peptidyl deformylase

INVENTOR(S): Patel, Dinesh V.; Yuan, Zhengyu; Jain, Rakesh K.; Garcia Alvarez, Salvador; Jacobs, Jeffrey

PATENT ASSIGNEE(S): Versicor, Inc., USA; Novartis AG

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102790	A1	20021227	WO 2002-EP6604	20020614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2003045479	A1	20030306	US 2002-171706	20020614
PRIORITY APPLN. INFO.:			US 2001-298419P	P 20010615
			US 2002-360313P	P 20020227

OTHER SOURCE(S): MARPAT 138:55863

GI



AB Title compds. I [X = CH₂, S, CHO, CH-alkoxy, CHSH, etc.; R1 = (hetero)aryl; R2-5 = H, alkyl, etc.; n = 0-3 provided that when n = 0, X = CH₂] are prep'd. For instance, (S)-2-(chlorocarbonyl)pyrrolidine-1-carboxylic acid benzyl ester is used to acylate 2-aminopyridine and the resulting amide deprotected and coupled to (2R)-2-[(benzyloxyformylamino)methyl]hexanoic acid (prepn. given; dioxane, HATU,

i-Pr₂NET) to give II. IC₅₀ of selected examples of I against MMP-7 ranges from >10 pM to >100 pM, whereas the IC₅₀ of these same compds. against zinc-contg. peptidyl deformylase (PDF) ranges from about 0.005 pM to 5 pM, and against nickel-contg. PDF ranges from about 0.001 pM to about 0.3 pM. I are useful for preventing contamination of a cell culture medium.

IC ICM C07D401-12
 ICS A61K031-4402; A61P031-04
 CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
 Section cross-reference(s): 1, 34, 63
 IT **478913-80-3P**
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of N-formyl-N-hydroxylamino-substituted pyrrolidine derivs. as inhibitors of peptidyl deformylase)

478912-45-7P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(pyridin-2-yl)amide **478912-48-0P**
 , (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(3-methylpyridin-2-yl)amide **478912-50-4P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(6-methylpyridin-2-yl)amide **478912-52-6P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4-methylpyridin-2-yl)amide **478912-56-0P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(5-fluoropyridin-2-yl)amide **478912-59-3P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide **478912-63-9P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(6-ethylpyridin-2-yl)amide **478912-66-2P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(5-trifluoromethylpyridin-2-yl)amide
478912-69-5P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(6-fluoropyridin-2-yl)amide
478912-76-4P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4,6-dimethyl-1-oxopyridin-2-yl)amide
478912-80-0P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4-methyl-1-oxopyridin-2-yl)amide
478912-85-5P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]azetidine-2-carboxylic acid N-(pyridin-2-yl)amide **478912-92-4P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4,6-dimethylpyridin-2-yl)amide **478912-97-9P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4-ethylpyridin-2-yl)amide **478913-05-2P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(3-hydroxypyridin-2-yl)amide **478913-12-1P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(isoquinolin-1-yl)amide **478913-16-5P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(quinolin-3-yl)amide **478913-21-2P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]azetidine-2-carboxylic acid N-(4-methylpyridin-2-yl)amide **478913-24-5P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]azetidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide **478913-27-8P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]azetidine-2-carboxylic acid N-(5-fluoropyridin-2-yl)amide **478913-30-3P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(5-trifluoromethyl-1-oxopyridin-2-yl)amide
478913-37-0P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]

pyrrolidine-2-carboxylic acid N-(4-phenylpyridin-2-yl)amide
478913-41-6P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]
 pyrrolidine-2-carboxylic acid N-(4-phenyl-1-oxopyridin-2-yl)amide
478913-45-0P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]
 pyrrolidine-2-carboxylic acid N-(4-trifluoromethylpyridin-2-yl)amide
478913-48-3P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]
 pyrrolidine-2-carboxylic acid N-(4-trifluoromethyl-1-oxopyridin-2-yl)amide
478913-51-8P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]
 pyrrolidine-2-carboxylic acid N-(8-hydroxyquinolin-2-yl)amide **478913-55-2P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidin
 e-2-carboxylic acid N-(3-methoxy-6-methylpyridin-2-yl)amide
478913-59-6P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]
 pyrrolidine-2-carboxylic acid N-(4-methoxypyridin-2-yl)amide
478913-64-3P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]
 pyrrolidine-2-carboxylic acid N-(3-methoxypyridin-2-yl)amide
 478913-68-7P, (2S)-1-[(2R)-2-[(Benzylxyformylamino)methyl]hexanoyl]pyrrol
 idine-2-carboxylic acid N-(3-methoxypyridin-2-yl)amide
478913-69-8P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]
 pyrrolidine-2-carboxylic acid N-(6-hydroxypyridin-2-yl)amide
 478913-70-1P, (S)-Pyrrolidine-2-carboxylic acid N-(6-benzylxypyridin-2-
 yl)amide **478913-75-6P**, (2S)-1-[(2R)-2-
 [(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid
 N-(3-hydroxy-1-oxopyridin-2-yl)amide **478913-83-6P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-
 carboxylic acid N-(2,2-difluorobenzo[1,3]dioxol-5-yl)amide
478913-87-0P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]
 pyrrolidine-2-carboxylic acid N-(3-phenoxyphenyl)amide
478913-91-6P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]
 pyrrolidine-2-carboxylic acid N-(5-fluoro-1-oxopyridin-2-yl)amide
478913-94-9P **478913-96-1P**, (2S,4R)-1-[(2R)-2-
 [(Formylhydroxyamino)methyl]hexanoyl]-4-hydroxypyrrrolidine-2-carboxylic
 acid N-(5-methylpyridine-2-yl)amide **478913-99-4P**,
 (2S,4S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]-4-
 hydroxypyrrrolidine-2-carboxylic acid N-(5-methylpyridine-2-yl)amide
478914-01-1P, (2S,4R)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexano
 yl]-4-hydroxypyrrrolidine-2-carboxylic acid N-(4-ethylpyridine-2-yl)amide
478914-03-3P, (2S,4R)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexano
 yl]-4-hydroxypyrrrolidine-2-carboxylic acid N-(5-trifluoromethylpyridine-2-
 yl)amide **478914-05-5P**, (2S,4S)-4-Fluoro-1-[(2R)-2-
 [(formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid
 N-(5-methylpyridine-2-yl)amide **478914-08-8P**,
 (2S,4R)-4-Fluoro-1-[(2R)-2-[(formylhydroxyamino)methyl]hexanoyl]pyrrolidin
 e-2-carboxylic acid N-(5-methylpyridine-2-yl)amide **478914-10-2P**
478914-12-4P, (2S,4R)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexano
 yl]-4-methoxypyrrrolidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide
478914-17-9P, (2S,4S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexano
 yl]-4-methoxypyrrrolidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide
479067-88-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of N-formyl-N-hydroxylamino-substituted pyrrolidine derivs. as
 inhibitors of peptidyl deformylase)

IT 13726-69-7P, (2S,4R)-4-Hydroxy-1-(tert-butoxycarbonyl)pyrrolidine-2-
 carboxylic acid 83623-93-2P, (2S,4S)-4-Methoxy-1-(tert-
 butoxycarbonyl)pyrrolidine-2-carboxylic acid 83624-01-5P,
 (2S,4R)-4-Methoxy-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid
 102195-79-9P, (2S,4S)-4-Hydroxy-2-(methoxycarbonyl)pyrrolidine-1-

carboxylic acid tert-butyl ester 102195-80-2P, (2S)-4-Oxo-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid methyl ester 153290-91-6P,
 (S)-Pyrrolidine-2-carboxylic acid N-(pyridin-2-yl)amide 215918-38-0P,
 (2S,4S)-4-Methoxy-2-(methoxycarbonyl)pyrrolidine-1-carboxylic acid
 tert-butyl ester 216682-25-6P 301685-23-4P, (2R)-2-[
 [(Benzyl oxyformylamino)methyl]hexanoic acid 426844-31-7P,
 (2S,4R)-4-Methoxy-2-(methoxycarbonyl)pyrrolidine-1-carboxylic acid
 tert-butyl ester 478912-40-2P, (S)-4-Benzyl-3-(n-butyl)acryloyl)oxazolidin-2-one 478912-42-4P 478912-43-5P,
 (4S)-4-Benzyl-3-[
 (2R)-2-((benzyl oxyamino)methyl)hexanoyl]oxazolidin-2-one
 478912-44-6P 478912-46-8P, (2S)-2-((Pyridin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid benzyl ester 478912-47-9P 478912-54-8P,
 (2S)-2-((4-Methylpyridin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid
 benzyl ester 478912-55-9P 478912-57-1P, (S)-Pyrrolidine-2-carboxylic acid N-(5-fluoropyridin-2-yl)amide 478912-58-2P 478912-61-7P,
 (S)-2-((5-Methylpyridin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid
 benzyl ester 478912-62-8P 478912-65-1P 478912-67-3P 478912-68-4P
 478912-71-9P, (6-Fluoropyridin-2-yl)(4-methoxybenzyl)amine 478912-72-0P,
 (2S)-2-((6-Fluoropyridin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid
 benzyl ester 478912-74-2P 478912-79-7P 478912-83-3P 478912-88-8P,
 (S)-2-((Pyridin-2-yl)carbamoyl)azetidine-1-carboxylic acid tert-butyl
 ester 478912-90-2P 478912-95-7P 478912-99-1P, (S)-Pyrrolidine-2-carboxylic acid N-(4-ethylpyridin-2-yl)amide 478913-01-8P,
 (2S)-2-((4-Ethylpyridin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid
 benzyl ester 478913-03-0P 478913-09-6P, (2S)-2-((3-Benzyl oxypyridin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid benzyl ester 478913-10-9P
 478913-11-0P, (2S)-1-[
 (2R)-2-[(Benzyl oxyformylamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(3-benzyloxy pyridin-2-yl)amide 478913-14-3P
 478913-15-4P, (2S)-1-[
 (2R)-2-[(Benzyl oxyformylamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(isoquinolin-1-yl)amide 478913-17-6P,
 (S)-Pyrrolidine-2-carboxylic acid N-(quinolin-3-yl)amide 478913-18-7P,
 (2S)-2-((Quinolin-3-yl)carbamoyl)pyrrolidine-1-carboxylic acid benzyl
 ester 478913-19-8P 478913-20-1P, (2S)-1-[
 (2R)-2-[(Benzyl oxyformylamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid
 N-(quinolin-3-yl)amide 478913-23-4P 478913-25-6P, (S)-Azetidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide 478913-26-7P
 478913-28-9P, (S)-Azetidine-2-carboxylic acid N-(5-fluoropyridin-2-yl)amide 478913-29-0P, (S)-2-((5-Fluoropyridin-2-yl)amino)carbonyl)azetidine hydrochloride 478913-31-4P,
 (S)-Pyrrolidine-2-carboxylic acid N-(5-trifluoromethyl-1-oxopyridin-2-yl)amide 478913-32-5P, (S)-2-((5-Trifluoromethyl-1-oxopyridin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid benzyl ester 478913-33-6P
 478913-34-7P, (S)-Pyrrolidine-2-carboxylic acid N-(4-ethyl-1-oxopyridin-2-yl)amide 478913-35-8P, (S)-2-((4-Ethyl-1-oxopyridin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid benzyl ester 478913-36-9P
 478913-38-1P, (S)-Pyrrolidine-2-carboxylic acid N-(4-phenylpyridin-2-yl)amide 478913-39-2P, (S)-2-((4-Phenylpyridin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid benzyl ester 478913-40-5P
 478913-42-7P, (S)-Pyrrolidine-2-carboxylic acid N-(4-phenyl-1-oxopyridin-2-yl)amide 478913-43-8P, (S)-2-((4-Phenyl-1-oxopyridin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid benzyl ester 478913-44-9P
 478913-46-1P, (S)-Pyrrolidine-2-carboxylic acid N-(4-trifluoromethylpyridin-2-yl)amide 478913-47-2P 478913-49-4P,
 (S)-Pyrrolidine-2-carboxylic acid N-(4-trifluoromethyl-1-oxopyridin-2-yl)amide 478913-50-7P 478913-52-9P, (S)-Pyrrolidine-2-carboxylic acid
 N-(8-benzyloxyquinolin-2-yl)amide 478913-53-0P, (S)-2-((8-Benzyloxyquinolin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid benzyl
 ester 478913-54-1P 478913-56-3P, (S)-Pyrrolidine-2-carboxylic acid

N-(3-methoxy-6-methylpyridin-2-yl)amide 478913-58-5P 478913-60-9P,
 (S)-Pyrrolidine-2-carboxylic acid N-(4-methoxypyridin-2-yl)amide
 478913-61-0P, (S)-2-[(4-Methoxypyridin-2-yl)carbamoyl]pyrrolidine-1-
 carboxylic acid benzyl ester 478913-62-1P 478913-63-2P,
 (2S)-1-[(2R)-2-[(Benzyl oxyformylamino)methyl]hexanoyl]pyrrolidine-2-
 carboxylic acid N-(4-methoxypyridin-2-yl)amide 478913-65-4P,
 (S)-Pyrrolidine-2-carboxylic acid N-(3-methoxypyridin-2-yl)amide
 478913-66-5P, (S)-2-[(3-Methoxypyridin-2-yl)carbamoyl]pyrrolidine-1-
 carboxylic acid benzyl ester 478913-67-6P 478913-71-2P,
 (S)-2-[(6-Hydroxypyridin-2-yl)carbamoyl]pyrrolidine-1-carboxylic acid
 benzyl ester 478913-72-3P, (S)-2-[(6-Benzyloxypyridin-2-
 yl)carbamoyl]pyrrolidine-1-carboxylic acid benzyl ester 478913-73-4P
 478913-74-5P, (2S)-1-[(2R)-2-[(Benzyl oxyformylamino)methyl]hexanoyl]pyrrol
 idine-2-carboxylic acid N-(6-benzyloxypyridin-2-yl)amide 478913-76-7P,
 (S)-Pyrrolidine-2-carboxylic acid N-(3-benzyloxy-1-oxopyridin-2-yl)amide
 478913-77-8P, (S)-2-[(3-Benzyloxy-1-oxopyridin-2-yl)carbamoyl]pyrrolidine-
 1-carboxylic acid benzyl ester 478913-78-9P 478913-79-0P,
 (2S)-1-[(2R)-2-[(Benzyl oxyformylamino)methyl]hexanoyl]pyrrolidine-2-
 carboxylic acid N-(3-benzyloxy-1-oxopyridin-2-yl)amide 478913-81-4P
 478913-82-5P 478913-84-7P, (S)-Pyrrolidine-2-carboxylic acid
 N-(2,2-difluorobenzo[1,3]dioxol-5-yl)amide 478913-85-8P,
 (S)-2-[(2,2-Difluorobenzo[1,3]dioxol-5-yl)carbamoyl]pyrrolidine-1-
 carboxylic acid benzyl ester 478913-86-9P 478913-88-1P,
 (S)-Pyrrolidine-2-carboxylic acid N-(3-phenoxyphenyl)amide 478913-89-2P,
 (S)-2-[(3-Phenoxyphenyl)carbamoyl]pyrrolidine-1-carboxylic acid benzyl
 ester 478913-90-5P 478913-92-7P, (2S)-1-[(2R)-2-
 [(Benzyl oxyformylamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid
 N-(5-fluoropyridin-2-yl)amide 478913-93-8P, (2S)-1-[(2R)-2-
 [(Benzyl oxyformylamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid
 N-(5-fluoro-1-oxopyridin-2-yl)amide 478913-97-2P, (2S,4R)-4-
 (Benzyl oxy)pyrrolidine-2-carboxylic acid N-(5-methylpyridine-2-yl)amide
478913-98-3P, (2S,4R)-4-(Benzyl oxy)-1-[(2R)-2-
 [(formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid
 N-(5-methylpyridine-2-yl)amide 478914-00-0P, (2S,4S)-4-
 (Benzoyloxy)pyrrolidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide
 478914-02-2P, (2S,4R)-4-Benzyl oxypyrrrolidine-2-carboxylic acid
 N-(4-ethylpyridine-2-yl)amide 478914-04-4P, (2S,4R)-4-
 Benzyl oxypyrrrolidine-2-carboxylic acid N-(5-trifluoromethylpyridine-2-
 yl)amide 478914-06-6P, (2S,4S)-4-Fluoropyrrolidine-2-carboxylic acid
 N-(5-methylpyridin-2-yl)amide 478914-07-7P, (2S,4R)-4-Hydroxypyrrrolidine-
 2-carboxylic acid N-(5-methylpyridine-2-yl)amide 478914-09-9P,
 (2S,4R)-4-Fluoropyrrolidine-2-carboxylic acid N-(5-methylpyridin-2-
 yl)amide 478914-11-3P, (2S)-4,4-Difluoropyrrolidine-2-carboxylic acid
 N-(5-methylpyridin-2-yl)amide 478914-13-5P, (2S,4R)-4-Methoxypyrrrolidine-
 2-carboxylic acid N-(5-methylpyridin-2-yl)amide 478914-14-6P,
 (2S,4R)-4-Methoxy-2-[(5-methylpyridin-2-yl)carbamoyl]pyrrolidine-1-
 carboxylic acid tert-butyl ester 478914-15-7P 478914-16-8P,
 (2S,4R)-1-[(2R)-2-[(Benzyl oxyformylamino)methyl]hexanoyl]-4-
 methoxypyrrrolidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide
 478914-18-0P, (2S,4S)-4-Methoxypyrrrolidine-2-carboxylic acid
 N-(5-methylpyridin-2-yl)amide 478914-19-1P, (2S,4S)-4-Methoxy-2-((5-
 methylpyridin-2-yl)carbamoyl)pyrrolidine-1-carboxylic acid tert-butyl
 ester 478914-20-4P 478914-21-5P, (2S,4S)-1-[(2R)-2-
 [(Benzyl oxyformylamino)methyl]hexanoyl]-4-methoxypyrrrolidine-2-carboxylic
 acid N-(5-methylpyridin-2-yl)amide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prep. of N-formyl-N-hydroxylamino-substituted pyrrolidine derivs. as

inhibitors of peptidyl deformylase)


IT 478913-80-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of N-formyl-N-hydroxylamino-substituted pyrrolidine derivs. as inhibitors of peptidyl deformylase)

RN 478913-80-3 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-1,3-benzodioxol-5-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 478912-45-7P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(pyridin-2-yl)amide 478912-48-0P
, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(3-methylpyridin-2-yl)amide 478912-50-4P,
(2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(6-methylpyridin-2-yl)amide 478912-52-6P,
(2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4-methylpyridin-2-yl)amide 478912-56-0P,
(2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(5-fluoropyridin-2-yl)amide 478912-59-3P,
(2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide 478912-63-9P,
(2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(6-ethylpyridin-2-yl)amide 478912-66-2P,
(2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(5-trifluoromethylpyridin-2-yl)amide 478912-69-5P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(6-fluoropyridin-2-yl)amide 478912-76-4P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4,6-dimethyl-1-oxypyridin-2-yl)amide 478912-80-0P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4-methyl-1-oxypyridin-2-yl)amide 478912-85-5P, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]azetidine-2-carboxylic acid N-(pyridin-2-yl)amide 478912-92-4P,
(2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4,6-dimethylpyridin-2-yl)amide 478912-97-9P,
(2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4-ethylpyridin-2-yl)amide 478913-05-2P,
(2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(3-hydroxypyridin-2-yl)amide 478913-12-1P,
(2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-

carboxylic acid N-(isoquinolin-1-yl)amide **478913-16-5P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(quinolin-3-yl)amide **478913-21-2P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]azetidine-2-carboxylic acid N-(4-methylpyridin-2-yl)amide **478913-24-5P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]azetidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide **478913-27-8P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]azetidine-2-carboxylic acid N-(5-fluoropyridin-2-yl)amide **478913-30-3P**,
 (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(5-trifluoromethyl-1-oxopyridin-2-yl)amide **478913-37-0P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4-phenylpyridin-2-yl)amide **478913-41-6P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4-phenyl-1-oxopyridin-2-yl)amide **478913-45-0P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4-trifluoromethylpyridin-2-yl)amide **478913-48-3P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4-trifluoromethyl-1-oxopyridin-2-yl)amide **478913-51-8P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(8-hydroxyquinolin-2-yl)amide **478913-55-2P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(3-methoxy-6-methylpyridin-2-yl)amide **478913-59-6P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(4-methoxypyridin-2-yl)amide **478913-64-3P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(3-methoxypyridin-2-yl)amide **478913-69-8P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(6-hydroxypyridin-2-yl)amide **478913-75-6P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(3-hydroxy-1-oxopyridin-2-yl)amide **478913-83-6P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(2,2-difluorobenz[1,3]dioxol-5-yl)amide **478913-87-0P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(3-phenoxyphenyl)amide **478913-91-6P**, (2S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(5-fluoro-1-oxopyridin-2-yl)amide **478913-94-9P** **478913-96-1P**, (2S,4R)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]-4-hydroxypyrrrolidine-2-carboxylic acid N-(5-methylpyridine-2-yl)amide **478913-99-4P**, (2S,4S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]-4-hydroxypyrrrolidine-2-carboxylic acid N-(5-methylpyridine-2-yl)amide **478914-01-1P**, (2S,4R)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]-4-hydroxypyrrrolidine-2-carboxylic acid N-(4-ethylpyridine-2-yl)amide **478914-03-3P**, (2S,4R)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]-4-hydroxypyrrrolidine-2-carboxylic acid N-(5-trifluoromethylpyridine-2-yl)amide **478914-05-5P**, (2S,4S)-4-Fluoro-1-[(2R)-2-[(formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid N-(5-methylpyridine-2-yl)amide **478914-08-8P**, (2S,4R)-4-Fluoro-1-[(2R)-2-[(formylhydroxyamino)methyl]hexanoyl]pyrrolidin e-2-carboxylic acid N-(5-methylpyridine-2-yl)amide **478914-10-2P** **478914-12-4P**, (2S,4R)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]-4-methoxypyrrrolidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide **478914-17-9P**, (2S,4S)-1-[(2R)-2-[(Formylhydroxyamino)methyl]hexanoyl]-4-methoxypyrrrolidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide **479067-88-4P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(prep. of N-formyl-N-hydroxylamino-substituted pyrrolidine derivs. as inhibitors of peptidyl deformylase)

RN 478912-45-7 HCAPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-48-0 HCAPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-50-4 HCAPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-52-6 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-56-0 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(5-fluoro-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-59-3 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-63-9 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(6-ethyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-66-2 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-69-5 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(6-fluoro-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-76-4 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(4,6-dimethyl-1-oxido-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-80-0 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(4-methyl-1-oxido-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-85-5 HCPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-N-2-pyridinyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-92-4 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(4,6-dimethyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478912-97-9 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(4-ethyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-05-2 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(3-hydroxy-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-12-1 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-1-isoquinolinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-16-5 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-3-quinolinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-21-2 HCPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-N-(4-methyl-2-pyridinyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-24-5 HCPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-N-(5-methyl-2-pyridinyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-27-8 HCPLUS

CN 2-Azetidinecarboxamide, N-(5-fluoro-2-pyridinyl)-1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-30-3 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-[1-oxido-5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-37-0 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(4-phenyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-41-6 HCPLUS


CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(1-oxido-4-phenyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478913-45-0 HCAPLUS
 CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-[4-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478913-48-3 HCAPLUS
 CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-[1-oxido-4-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478913-51-8 HCAPLUS
 CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(8-hydroxy-2-quinolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-55-2 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(3-methoxy-6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-59-6 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(4-methoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-64-3 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(3-methoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-69-8 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(1,6-dihydro-6-oxo-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-75-6 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(3-hydroxy-1-oxido-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-83-6 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(2,2-difluoro-1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-87-0 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-91-6 HCPLUS


CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(5-fluoro-1-oxido-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478913-94-9 HCAPLUS
 CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-[5-(methoxycarbonyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478913-96-1 HCAPLUS
 CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-4-hydroxy-N-(5-methyl-2-pyridinyl)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478913-99-4 HCAPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-4-hydroxy-N-(5-methyl-2-pyridinyl)-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478914-01-1 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(4-ethyl-2-pyridinyl)-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478914-03-3 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-4-hydroxy-N-[5-(trifluoromethyl)-2-pyridinyl]-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478914-05-5 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-4-fluoro-N-(5-methyl-2-pyridinyl)-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478914-08-8 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-4-fluoro-N-(5-methyl-2-pyridinyl)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478914-10-2 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-4,4-difluoro-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478914-12-4 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-4-methoxy-N-(5-methyl-2-pyridinyl)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478914-17-9 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-4-methoxy-N-(5-methyl-2-pyridinyl)-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 479067-88-4 HCPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(4-ethyl-1-oxido-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 478913-98-3P, (2S,4R)-4-(Benzylxylo)-1-[(2R)-2-[(formylhydroxyamino)methyl]hexanoyl]pyrrolidine-2-carboxylic acid
N-(5-methylpyridine-2-yl)amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-formyl-N-hydroxylamino-substituted pyrrolidine derivs. as inhibitors of peptidyl deformylase)

RN 478913-98-3 HCAPLUS

CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(5-methyl-2-pyridinyl)-4-(phenylmethoxy)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:435770 HCAPLUS
 DOCUMENT NUMBER: 137:165443
 TITLE: Crystal Structure of Human MMP9 in Complex with a Reverse Hydroxamate Inhibitor
 AUTHOR(S): Rowsell, Sin; Hawtin, Paul; Minshull, Claire A.; Jepson, Holly; Brockbank, Sarah M. V.; Barratt, Derek G.; Slater, Anthony M.; McPheat, William L.; Waterson, David; Henney, Adriano M.; Paupert, Richard A.
 CORPORATE SOURCE: AstraZeneca, Macclesfield, Cheshire, SK10 4TG, UK
 SOURCE: Journal of Molecular Biology (2002), 319(1), 173-181
 CODEN: JMOBAK; ISSN: 0022-2836
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Matrix metalloproteinases (MMPs) and their inhibitors are important in connective tissue re-modeling in diseases of the cardiovascular system, such as atherosclerosis. Various members of the MMP family have been shown to be expressed in atherosclerotic lesions, but MMP9 is consistently seen in inflammatory atherosclerotic lesions. MMP9 over-expression is implicated in the vascular re-modeling events preceding plaque rupture (the most common cause of acute myocardial infarction). Reduced MMP9 activity, either by genetic manipulation or through pharmacol. intervention, has an impact on ventricular re-modeling following infarction. MMP9 activity may therefore represent a key mechanism in the pathogenesis of heart failure. We have detd. the crystal structure, at

2.3 resoln., of the catalytic domain of human MMP9 bound to a peptidic reverse hydroxamate inhibitor as well as the complex of the same inhibitor bound to an active-site mutant (E402Q) at 2.1 resoln. MMP9 adopts the typical MMP fold. The catalytic center is composed of the active-site zinc ion, coordinated by three histidine residues (401, 405 and 411) and the essential glutamic acid residue (402). The main differences between the catalytic domains of various MMPs occur in the S1' subsite or selectivity pocket. The S1' specificity site in MMP9 is perhaps best described as a tunnel leading toward solvent, as in MMP2 and MMP13, as opposed to the smaller pocket found in fibroblast collagenase and matriLySIN. The present structure enables us to aid the design of potent and specific inhibitors for this important cardiovascular disease target.

CC 7-5 (Enzymes)

IT Section cross-reference(s): 75

IT 56-86-0D, L-Glutamic acid, complexes with reverse hydroxamate inhibitor 71-00-1, L-Histidine, biological studies 4312-87-2, N-Formylhydroxylamine 7440-66-6, Zinc, biological studies 146480-36-6D, MMP 9, complexes with reverse hydroxamate inhibitor **448297-71-0**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(crystal structure of human MMP9 in complex with reverse hydroxamate inhibitor reveals catalytic center is composed of active-site zinc ion coordinated by three histidine residues and essential glutamic acid residue)

IT **448297-71-0**


RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(crystal structure of human MMP9 in complex with reverse hydroxamate inhibitor reveals catalytic center is composed of active-site zinc ion coordinated by three histidine residues and essential glutamic acid residue)

RN 448297-71-0 HCAPLUS

CN L-Valinamide, N-formyl-N-hydroxy-2-(2-methylpropyl)-.beta.-alanyl-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:240074 HCAPLUS

DOCUMENT NUMBER: 136:398389

TITLE: In vitro activities of peptide deformylase inhibitors against gram-positive pathogens

AUTHOR(S): Wise, R.; Andrews, J. M.; Ashby, J.

CORPORATE SOURCE: Department of Microbiology, City Hospital NHS Trust, Birmingham, UK
 SOURCE: Antimicrobial Agents and Chemotherapy (2002), 46(4), 1117-1118
 CODEN: AMACQ; ISSN: 0066-4804
 PUBLISHER: American Society for Microbiology
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The activities of 6 peptide deformylase (PDF) inhibitors against 107 respiratory tract pathogens were studied and compared to those of ciprofloxacin and amoxicillin-clavulanate. Against *Streptococcus pneumoniae*, BB-83698 and BB-83815 were the most active PDF inhibitors (MIC at which 90% of the organisms tested were inhibited [MIC90], 0.25 .mu.g/mL). 5 Of the agents showed similar activity against *Moraxella catarrhalis* (MIC90, 0.12 .mu.g/mL). All PDF inhibitors were less active against *Haemophilus influenzae*; BB-3497 was the most active agent (MIC90, 2 .mu.g/mL). Five agents were studied against *Chlamydia* spp. and showed activity similar to that of ciprofloxacin (MIC, 0.5 to 4 .mu.g/mL). This study demonstrates that PDF inhibitors have the potential to be developed for the treatment of respiratory tract infections.

CC 10-5 (Microbial, Algal, and Fungal Biochemistry)
 IT 1406-05-9, Penicillin 79198-29-1 85721-33-1, Ciprofloxacin
235784-88-0, BB 3497 428862-38-8, BB 83698 428862-40-2, BB
 83815 428862-41-3, BB 83857 428862-43-5, BB 84416 428862-46-8, BB
 84518

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(in vitro activities of peptide deformylase inhibitors against gram-pos. pathogens compared with penicillin, ciprofloxacin, and amoxicillin-clavulanate)


IT **235784-88-0**, BB 3497
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(in vitro activities of peptide deformylase inhibitors against gram-pos. pathogens compared with penicillin, ciprofloxacin, and amoxicillin-clavulanate)

RN 235784-88-0 HCAPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2001:674624 HCAPLUS
 DOCUMENT NUMBER: 136:6325
 TITLE: Asymmetric synthesis of BB-3497-A potent peptide deformylase inhibitor
 AUTHOR(S): Pratt, L. M.; Beckett, R. P.; Davies, S. J.; Launchbury, S. B.; Miller, A.; Spavold, Z. M.; Todd, R. S.; Whittaker, M.
 CORPORATE SOURCE: British Biotech Pharmaceuticals Limited, Cowley, Oxford, OX4 6LY, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(19), 2585-2588
 CODEN: BMCL8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB By screening a library of metalloenzyme inhibitors, the N-formyl-hydroxylamine deriv. BB-3497 was identified as a potent inhibitor of Escherichia coli peptide deformylase with antibacterial activity both in vitro and in vivo. The homochiral synthesis of BB-3497, involving a novel asym. Michael addn. reaction is described.
 CC 34-3 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 1, 7, 63
 IT 235784-88-0P 235785-83-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (asym. synthesis of BB-3497-A via asym. Michael addn. as potent inhibitor of Escherichia coli peptide deformylase)
 IT 235784-88-0P 235785-83-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (asym. synthesis of BB-3497-A via asym. Michael addn. as potent inhibitor of Escherichia coli peptide deformylase)
 RN 235784-88-0 HCAPLUS
 CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235785-83-8 HCAPLUS
 CN L-Valinamide, (2S)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:115119 HCAPLUS

DOCUMENT NUMBER: 134:162573

TITLE: Preparation of N-formyl hydroxylamine derivatives as antibacterial agents

INVENTOR(S): Hunter, Michael George; Beckett, Raymond Paul; Clements, John Martin; Whittaker, Mark; Davies, Stephen John; Pratt, Lisa Marie; Spavold, Zoe Marie; Launchbury, Steven

PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Limited, UK

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010835	A1	20010215	WO 1999-GB2629	19990810
W: AU, BR, CA, CN, CZ, GB, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9952961	A1	20010305	AU 1999-52961	19990810
EP 1210330	A1	20020605	EP 1999-938453	19990810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

PRIORITY APPLN. INFO.: WO 1999-GB2629 A 19990810

OTHER SOURCE(S): MARPAT 134:162573

AB Selected compds. $\text{HC(O)CH(OH)CH(R2)C(O)A}$ (I; e.g. N-[1S-(4-benzylpiperidine-1-carbonyl)-2,2-dimethylpropyl]-3-cyclopentyl-2R-[(formylhydroxyamino)methyl]propionamide) and pharmaceutical and veterinary compns. comprising such compds. are antibacterial agents with respect to a range of Gram-pos. and Gram-neg. organisms. In I, R2 = substituted or unsubstituted C1-C6 alkyl, cycloalkyl(C1-C6 alkyl)- or aryl(C1-C6 alkyl)- group; and A = NHCHR4C(O)NR5R6 or NR5R6 (R4 = side chain of a natural or non-natural alpha amino acid; R5 and R6 = independently H or C1-C6 alkyl, heterocyclic or aryl(C1-C6 alkyl)-, R5 and R6 when taken together with the N atom to which they are attached from an optionally substituted satd. heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or 2nd heterocyclic ring). The claimed compds. inhibit bacterial polypeptide deformylase (PDF; EC

3.5.1.31), but quant. data are not given. Although the methods of prepn. are not claimed, 27 example preps. are included.

IC ICM C07D211-16
 ICS C07D295-18; A61K031-16; C07D295-22; C07C259-06; C07D211-60;
 C07D295-20; C07D217-06; C07D211-48; C07C321-16; C07C279-14;
 A61K031-445; A61K031-495; A61K031-47; A61P031-04; C07D211-58

CC 21-2 (General Organic Chemistry)
 Section cross-reference(s): 1, 10, 27, 28, 34, 63

IT 325459-35-6P, N-[1S-(4-Benzylpiperidine-1-carbonyl)-2,2-dimethylpropyl]-3-cyclopentyl-2R-[(formylhydroxyamino)methyl]propionamide
325459-36-7P, N-[2R-(4-Benzylpiperidine-1-carbonyl)hexyl]-N-hydroxyformamide **325459-37-8P**, N-Hydroxy-N-[2R-(2-methylpiperidine-1-carbonyl)hexyl]formamide **325459-38-9P**, N-Hydroxy-N-[2R-(piperidine-1-carbonyl)hexyl]formamide
325459-39-0P, N-Hydroxy-N-[2R-(piperazine-1-carbonyl)hexyl]formamide 325459-40-3P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid pyrrolidin-1-ylamide 325459-41-4P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid methyl(1-methylpiperidin-4-yl)amide **325459-42-5P**, N-[2R-(Azepane-1-carbonyl)hexyl]-N-hydroxyformamide 325459-43-6P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid (4-methylpiperazin-1-yl)amide 325459-44-7P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid diisopropylamide
325459-45-8P, 1-{2R-[(Formylhydroxyamino)methyl]hexanoyl}piperidin-e-3-carboxylic acid ethyl ester **325459-46-9P**, 4-{2R-[(Formylhydroxyamino)methyl]hexanoyl}piperazine-1-carboxylic acid ethyl ester **325459-47-0P**, 4-{2R-[(Formylhydroxyamino)methyl]hexanoyl}-1,1-dimethylpiperazinium iodide 325459-48-1P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid [2,2-dimethyl-1S-(piperidine-1-carbonyl)propyl]amide 325459-49-2P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid [1S-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-2,2-dimethylpropyl]amide 325459-50-5P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid [1S-(4-benzyl-4-hydroxypiperidine-1-carbonyl)-2,2-dimethylpropyl]amide 325459-51-6P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid [1S-(4-benzylpiperazine-1-carbonyl)-2,2-dimethylpropyl]amide
325459-52-7P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid (3-benzylthio-1S-dimethylcarbamoylpropyl)amide **325459-53-8P**, 3S-{2R-[(Formylhydroxyamino)methyl]hexanoylamino}-N,N-dimethylsuccinamic acid benzyl ester **325459-54-9P**, 4S-Dimethylcarbamoyl-4-{2R-[(formylhydroxyamino)methyl]hexanoylamino}butyric acid benzyl ester
325459-55-0P, (5S-Dimethylcarbamoyl-5-{2R-[(formylhydroxyamino)methyl]hexanoylamino}pentyl)dimethylammonium chloride
325459-56-1P, 2R-[(Formylhydroxyamino)methyl]butyric acid (1S-1-dimethylcarbamoyl-2,2-dimethylpropyl)amide **325459-57-2P**, 2R-[(Formylhydroxyamino)methyl]hexanoic acid (1S-carbamoyl-2,2-dimethylpropyl)amide **325459-58-3P**, 2R-[(Formylhydroxyamino)methyl]hexanoic acid (1S-dimethylcarbamoyl-4-guanidinobutyl)amide 325459-59-4P, [2R-2-(4-Chlorophenyl)-3-(formylhydroxyamino)propionylamino]-2S-3,3,N,N-tetramethylbutyramide 325459-60-7P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid [2(3,4-dihydroxyphenyl)ethyl]amide 325459-61-8P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid [2(4-hydroxyphenyl)ethyl]amide
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-formyl hydroxylamine derivs. as antibacterial agents)

IT 109-01-3, N-Methylpiperazine 534-59-8, n-Butylmalonic acid 622-33-3, O-Benzylhydroxylamine 771-61-9, Pentafluorophenol 3282-30-2, Pivaloyl chloride 13139-17-8, N-(Benzoyloxycarbonyloxy)succinimide 20859-02-3,

L-tert-Leucine 31252-42-3, 4-Benzylpiperidine 143415-28-5,
 4S-Benzyl-3-(3-cyclopentylpropionyl)oxazolidin-2-one 235785-22-5
 , N-Hydroxy-N-[2R-(4-methylpiperazine-1-carbonyl)hexyl]formamide

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prep. of N-formyl hydroxylamine derivs. as antibacterial agents)


IT 325459-36-7P, N-[2R-(4-Benzylpiperidine-1-carbonyl)hexyl]-N-hydroxyformamide 325459-37-8P, N-Hydroxy-N-[2R-(2-methylpiperidine-1-carbonyl)hexyl]formamide 325459-38-9P, N-Hydroxy-N-[2R-(piperidine-1-carbonyl)hexyl]formamide 325459-39-0P, N-Hydroxy-N-[2R-(piperazine-1-carbonyl)hexyl]formamide 325459-42-5P, N-[2R-(Azepane-1-carbonyl)hexyl]-N-hydroxyformamide 325459-45-8P, 1-{2R-[(Formylhydroxyamino)methyl]hexanoyl}piperidine-3-carboxylic acid ethyl ester 325459-46-9P, 4-{2R-[(Formylhydroxyamino)methyl]hexanoyl}piperazine-1-carboxylic acid ethyl ester 325459-47-0P, 4-{2R-[(Formylhydroxyamino)methyl]hexanoyl}-1,1-dimethylpiperazinium iodide 325459-52-7P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid (3-benzylthio-1S-dimethylcarbamoylpropyl)amide 325459-53-8P, 3S-{2R-[(Formylhydroxyamino)methyl]hexanoylamino}-N,N-dimethylsuccinamic acid benzyl ester 325459-54-9P, 4S-Dimethylcarbamoyl-4-{2R-[(formylhydroxyamino)methyl]hexanoylamino}butyric acid benzyl ester 325459-55-0P, (5S-Dimethylcarbamoyl-5-{2R-[(formylhydroxyamino)methyl]hexanoylamino}pentyl)dimethylammonium chloride 325459-56-1P, 2R-[(Formylhydroxyamino)methyl]butyric acid (1S-1-dimethylcarbamoyl-2,2-dimethylpropyl)amide 325459-57-2P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid (1S-carbamoyl-2,2-dimethylpropyl)amide 325459-58-3P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid (1S-dimethylcarbamoyl-4-guanidinobutyl)amide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of N-formyl hydroxylamine derivs. as antibacterial agents)

RN 325459-36-7 HCPLUS

CN Piperidine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325459-37-8 HCPLUS


CN Piperidine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325459-38-9 HCPLUS
CN Piperidine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325459-39-0 HCPLUS
CN Piperazine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325459-42-5 HCPLUS
CN 1H-Azepine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]hexahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325459-45-8 HCAPLUS
 CN 3-Piperidinecarboxylic acid, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325459-46-9 HCAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325459-47-0 HCAPLUS
 CN Piperazinium, 4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-1,1-dimethyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● I-

RN 325459-52-7 HCPLUS

CN L-Homocysteinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl-S-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325459-53-8 HCPLUS

CN L-.alpha.-Asparagine, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325459-54-9 HCPLUS

CN L-.alpha.-Glutamine, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325459-55-0 HCPLUS

CN L-Lysinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N,N6,N6-tetramethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 325459-56-1 HCPLUS

CN L-Valinamide, (2R)-2-ethyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325459-57-2 HCPLUS


CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325459-58-3 HCAPLUS
 CN L-Argininamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 235785-22-5, N-Hydroxy-N-[2R-(4-methylpiperazine-1-carbonyl)hexyl]formamide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; prepn. of N-formyl hydroxylamine derivs. as antibacterial agents)
 RN 235785-22-5 HCAPLUS
 CN Piperazine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:115118 HCAPLUS

DOCUMENT NUMBER: 134:163065
 TITLE: Preparation of hydroxamic acid and N-formyl hydroxylamine derivatives as antibacterial agents
 INVENTOR(S): Pratt, Lisa Marie; Keavey, Kenneth Noel; Pain, Gilles Denis; Mounier, Laurent Franck
 PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Limited, UK
 SOURCE: PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010834	A2	20010215	WO 2000-GB3078	20000810
WO 2001010834	A3	20010628		
W: AE, AU, BR, BY, CA, CN, CZ, DZ, EE, GB, GE, HU, ID, IL, IN, IS, JP, KE, KR, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, US, VN, ZA, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1202968	A2	20020508	EP 2000-949820	20000810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY				
BR 2000013112	A	20020611	BR 2000-13112	20000810
JP 2003506438	T2	20030218	JP 2001-515301	20000810
NO 2002000621	A	20020409	NO 2002-621	20020208
PRIORITY APPLN. INFO.:			GB 1999-18869 A 19990810	
			GB 1999-27093 A 19991116	
			WO 2000-GB3078 W 20000810	

OTHER SOURCE(S): MARPAT 134:163065

AB Selected compds. QCH(R1)CH(R2)C(O)A (I) and pharmaceutical and veterinary compns. comprising such compds. are antibacterial agents with respect to a range of Gram-pos. and Gram-neg. organisms. In I, Q = -N(OH)C(O)H or -C(O)NH(OH); R1 = H, C1-C6 alkyl or C1-C6 alkyl substituted by .gtoreq. halogen atoms, or, except when Q is -N(OH)C(O)H, hydroxy, C1-C6 alkoxy, C1-C6 alkenyloxy, amino, C1-C6 alkylamino, or di-(C1-C6 alkyl)amino; R2 = substituted or unsubstituted C1-C6 alkyl, cycloalkyl(C1-C6 alkyl)- or aryl(C1-C6 alkyl)-; and A = -NHCHR4C(O)NR5R6 or -NR5R6, wherein R4 = side chain of a natural or non-natural .alpha.-amino acid, and R5 and R6 when taken together with the N atom to which they are attached form a satd. heterocyclic 1st ring of 5 to 7 atoms (piperidine and piperazine in the examples). In general, the compds. of the examples are more active against the Gram pos. S. capitis than the Gram neg. E. coli. Test results are also reported for 2R-cyclopentylmethyl-3-(formylhydroxyamino)-N-(1S-[4-[4-(4-hydroxypiperidine-1-carbonyl)phenoxy]piperidine-1-carbonyl]-2,2-dimethylpropyl)propionamide against certain respiratory tract pathogens. Although the methods of prepn. are not claimed, .apprx.95 example preps. are included.

IC ICM C07D211-00
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 10, 27, 34, 63
 IT 325795-25-3P 325795-27-5P 325795-29-7P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]-2,2-dimethylpropyl}amide
 325795-37-7P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid
 [1S-(4-benzotriazol-1-yl)piperidine-1-carbonyl]-2,2-dimethylpropyl]amide
 325795-38-8P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid

{1S-[4-benzo[1,3]dioxol-5-ylmethylpiperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325795-39-9P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid [2,2-dimethyl-1S-(4-phenylpiperidine-1-carbonyl)propyl]amide
 325795-40-2P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid
 {1S-(6,7-dimethoxy-3,4-dihydro-1H-isquinoline-2-carbonyl)-2,2-dimethylpropyl}amide 325795-41-3P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(4-fluorophenyl)piperidine-1-carbonyl]-2,2-dimethylpropyl}amide 325795-42-4P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {2,2-dimethyl-1S-[4-(2-oxo-2,3-dihydrobenzimidazol-1-yl)piperidine-1-carbonyl]propyl}amide 325795-43-5P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-(4-benzoylpiperidine-1-carbonyl)-2,2-dimethylpropyl}amide 325795-44-6P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-(4-benzhydrylpiperazine-1-carbonyl)-2,2-dimethylpropyl}amide 325795-45-7P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(2,5-dimethylphenyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325795-46-8P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(2-methoxyphenyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325795-47-9P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(furan-3-carbonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325795-48-0P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(5-furan-2-yl-2H-pyrazol-3-yl)piperidine-1-carbonyl]-2,2-dimethylpropyl}amide 325795-49-1P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {2,2-dimethyl-1S-[4-(5-phenyl-2H-pyrazol-3-yl)piperidine-1-carbonyl]propyl}amide 325795-50-4P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(4-methoxyphenyl)-3-methylpiperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325795-51-5P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydro-1H-isquinoline-2-carbonyl]-2,2-dimethylpropyl}amide 325795-52-6P, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(5-(2-chlorophenyl)-2H-pyrazol-3-yl)piperidine-1-carbonyl]-2,2-dimethylpropyl}amide
325795-53-7P, N-Hydroxy-N-[2R-(4-pyrimidin-2-yl)piperazine-1-carbonyl]hexyl]formamide **325795-54-8P**, N-{2R-[4-(4-Chlorophenyl)piperazine-1-carbonyl]hexyl}-N-hydroxyformamide
325795-55-9P, N-{2R-[4-Benzo(1,3)dioxol-5-ylmethylpiperazine-1-carbonyl]hexyl}-N-hydroxyformamide **325795-56-0P**, N-Hydroxy-N-{2R-[4-(4-methoxyphenyl)-3-methylpiperazine-1-carbonyl]hexyl}formamide **325795-57-1P**, N-{2R-[4-(4-Acetylphenyl)piperazine-1-carbonyl]hexyl}-N-hydroxyformamide
325795-58-2P, N-[2R-(4-Benzhydrylpiperazine-1-carbonyl)hexyl]-N-hydroxyformamide **325795-59-3P**, N-Hydroxy-N-[2R-(4-phenylpiperidine-1-carbonyl)hexyl]formamide **325795-60-6P**, N-Hydroxy-N-[2R-[4-(hydroxydiphenylmethyl)piperidine-1-carbonyl]hexyl]formamide **325795-61-7P**, N-Hydroxy-N-[2R-(4-phenylpiperazine-1-carbonyl)hexyl]formamide **325795-62-8P**, N-(2R-{4-[4-Chlorophenyl]phenylmethyl)piperazine-1-carbonyl}hexyl)-N-hydroxyformamide **325795-63-9P**, N-{2R-[4-(3-Chlorophenyl)piperazine-1-carbonyl]hexyl}-N-hydroxyformamide
325795-65-1P, N-Hydroxy-N-(2R-{4-[2-hydroxyethoxy)ethyl)piperazine-1-carbonyl}hexyl)formamide
325795-67-3P, N-Hydroxy-N-{2R-[4-(3-hydroxypropyl)piperazine-1-carbonyl]hexyl}formamide **325795-68-4P**, N-Hydroxy-N-{2R-[2-(2-hydroxyethyl)piperazine-1-carbonyl]hexyl}formamide **325795-70-8P**, N-{2R-[4-(3,4-Dichlorophenyl)piperazine-1-carbonyl]hexyl}-N-hydroxyformamide **325795-71-9P**, N-Hydroxy-N-{2R-[4-(4-methoxyphenyl)piperazine-1-carbonyl]hexyl}formamide **325795-72-0P**, N-Hydroxy-N-{2R-[4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carbonyl]hexyl}formamide **325795-73-1P**, N-Hydroxy-N-{2R-[4-(1H-

indol-4-yl)piperazine-1-carbonyl]hexyl}formamide **325795-74-2P**,
 N-(2R-{4-[Bis(4-fluorophenyl)methyl]piperazine-1-carbonyl}hexyl)-N-hydroxyformamide **325795-75-3P**, N-Hydroxy-N-{2R-[4-(4-nitrophenyl)piperazine-1-carbonyl]hexyl}formamide **325795-76-4P**,
 N-{2R-[4-(4-Fluorophenyl)piperazine-1-carbonyl]hexyl}-N-hydroxyformamide **325795-77-5P**, N-{2R-[4-(Furan-2-carbonyl)piperazine-1-carbonyl]hexyl}-N-hydroxyformamide **325795-78-6P**,
 N-{2R-[4-(2,5-Dimethylphenyl)piperazine-1-carbonyl]hexyl}-N-hydroxyformamide **325795-80-0P**, 3R-Cyclopentylmethyl-4-[4-(4-fluorophenyl)piperazin-1-yl]-N-hydroxy-4-oxobutyramide **325795-83-3P**,
 3R-Cyclopentylmethyl-4-[4-(3,4-dichlorophenyl)piperazin-1-yl]-N-hydroxy-4-oxobutyramide **325795-84-4P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid
 {1S-[4-(4-cyanobenzyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide **325795-88-8P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid
 {1S-[4-(2-cyanobenzyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide **325795-89-9P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid
 {1S-[4-(3-cyanobenzyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide **325795-90-2P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid
 {1S-(4-biphenyl-4-ylmethyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide **325795-91-3P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid
 [1S-(4-biphenyl-2-ylmethyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide **325795-92-4P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid
 [2,2-dimethyl-1S-(4-naphthalen-2-ylmethyl)piperazine-1-carbonyl]propyl]amide **325795-93-5P**, N-{1S-[4-(4-Cyanobenzyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}-2R-cyclopentylmethyl-3-(formylhydroxyamino)propionamide **325795-94-6P**, N-{1S-[4-(2-Cyanobenzyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}-2R-cyclopentylmethyl-3-(formylhydroxyamino)propionamide **325795-95-7P**,
 N-{1S-[4-(3-Cyanobenzyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}-2S-cyclopentylmethyl-3-(formylhydroxyamino)propionamide **325795-97-9P**,
 N-[1S-(4-Biphenyl-4-ylmethyl)piperazine-1-carbonyl]-2,2-dimethylpropyl]-2R-(cyclopentylmethyl)-3-(formylhydroxyamino)propionamide **325795-98-0P**,
 N-[1S-(4-Biphenyl-2-ylmethyl)piperazine-1-carbonyl]-2,2-dimethylpropyl]-2R-cyclopentylmethyl-3-(formylhydroxyamino)propionamide **325795-99-1P**,
 2R-Cyclopentylmethyl-N-[2,2-dimethyl-1S-(4-naphthalen-2-ylmethyl)piperazine-1-carbonyl]propyl]-3-(formylhydroxyamino)propionamide **325796-00-7P**,
 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[4-[benzo[1,3]dioxole-5-carbonyl]piperazine-1-carbonyl]-2,2-dimethylpropyl}amide **325796-04-1P**,
 2R-[{Formylhydroxyamino)methyl]hexanoic acid [2,2-dimethyl-1S-(4-pyridin-3-ylmethyl)piperazine-1-carbonyl]propyl]amide **325796-07-4P**,
 2R-[{Formylhydroxyamino)methyl]hexanoic acid {2,2-dimethyl-1S-[4-(5-methylpyrazine-2-carbonyl)piperazine-1-carbonyl]propyl}amide **325796-08-5P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid
 {1S-[4-(4-acetyl-3,5-dimethyl-1H-pyrrole-2-carbonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide **325796-09-6P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {2,2-dimethyl-1S-[4-(5-methyl-1H-pyrazole-3-carbonyl)piperazine-1-carbonyl]propyl}amide **325796-10-9P**,
 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(2,5-dimethyl-2H-pyrazole-3-carbonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide **325796-11-0P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid
 {2,2-dimethyl-1S-[4-(1-H-pyrrole-2-carbonyl)piperazine-1-carbonyl]propyl}amide **325796-12-1P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {2,2-dimethyl-1S-[4-(pyridine-3-carbonyl)piperazine-1-carbonyl]propyl}amide **325796-13-2P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(2-hydroxypyridine-3-carbonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide **325796-14-3P**, 2R-[{Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(2,6-dihydroxypyrimidine-4-carbonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide **325796-15-4P**, 2R-[{Formylhydroxyamino)methyl]

xanoic acid {2,2-dimethyl-1S-[4-(pyrazine-2-carbonyl)piperazine-1-carbonyl]propyl}amide 325796-16-5P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {2,2-dimethyl-1S-[4-(5-methylisoxazole-3-carbonyl)piperazine-1-carbonyl]propyl}amide 325796-17-6P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {2,2-dimethyl-1S-[4-(thiophene-2-carbonyl)piperazine-1-carbonyl]propyl}amide 325796-18-7P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {2,2-dimethyl-1S-[4-[4-methyl-1,2,3-thiadiazole-5-carbonyl]piperazine-1-carbonyl]propyl}amide 325796-19-8P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(3,5-dimethylisoxazole-4-carbonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325796-20-1P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(isoxazole-5-carbonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325796-21-2P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {2,2-dimethyl-1S-[4-(2-pyridin-4-ylthiazole-4-carbonyl)piperazine-1-carbonyl]propyl}amide 325796-22-3P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(5-methanesulfonylthiophene-2-carbonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325796-23-4P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(2,4-dimethylthiazole-5-carbonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325796-24-5P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(2-chloropyridine-3-carbonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325796-25-6P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {2,2-dimethyl-1S-[4-(pyridine-2-carbonyl)piperazine-1-carbonyl]propyl}amide 325796-26-7P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {2,2-dimethyl-1S-[4-(1-methyl-1H-pyrrole-2-carbonyl)piperazine-1-carbonyl]propyl}amide 325796-27-8P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(biphenyl-4-sulfonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325796-28-9P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid {1S-[4-(biphenyl-4-carbonyl)piperazine-1-carbonyl]-2,2-dimethylpropyl}amide 325796-29-0P 325796-30-3P 325796-31-4P 325796-36-9P, 2R-[(Formylhydroxyamino)methyl]hexanoic acid [2,2-dimethyl-1S-(4-pyrimidin-2-ylpiperazine-1-carbonyl)propyl]amide 325796-37-0P, N1-(1S-{4-[1,3-Benzodioxole-5-carbonyl]}piperazine-1-carbonyl)-2,2-dimethylpropyl)-2R-cyclopentylmethyl-N4-hydroxysuccinamide 325796-46-1P, N1-[1S-(4-Biphenyl-4-ylmethypiperazine-1-carbonyl)-2,2-dimethylpropyl]-2R-cyclopentylmethyl-N4-hydroxysuccinamide 325796-47-2P, 2R-Cyclopentylmethyl-N1-[2,2-dimethyl-1S-(4-naphthalen-2-ylmethypiperazine-1-carbonyl)propyl]-N4-hydroxysuccinamide 325796-48-3P, 2R-Cyclopentylmethyl-N1-[2,2-dimethyl-1S-(4-pyridin-3-ylmethypiperazine-1-carbonyl)propyl]-N4-hydroxysuccinamide 325796-56-3P, 4-(1S-{2-[2R-Cyclopentylmethyl-3-(formylhydroxyamino)propionylamino]-3,3-dimethylbutyryl}piperidin-4-yloxy)-N,N-dimethylbenzamide 325796-57-4P, 4-(1-{2S-[3-(Benzylhydroxyformylamino)-2R-cyclopentylmethylpropionylamino]-3,3-dimethylbutyryl}piperidin-4-yloxy)-N-methylbenzamide 325796-58-5P, 2R-Cyclopentylmethyl-N-(2,2-dimethyl-1S-{4-[4-(morpholine-4-carbonyl)phenoxy]piperidine-1-carbonyl}propyl)-3-(formylhydroxyamino)propionamide 325796-59-6P, 2R-Cyclopentylmethyl-N-(2,2-dimethyl-1S-{4-[4-(4-methylpiperazine-1-carbonyl)phenoxy]piperidine-1-carbonyl}propyl)-3-(formylhydroxyamino)propionamide 325796-60-9P, 2R-Cyclopentylmethyl-3-(formylhydroxyamino)-N-(1S-{4-[4-(4-hydroxypiperidine-1-carbonyl)phenoxy]piperidine-1-carbonyl}-2,2-dimethylpropyl)propionamide 325796-61-0P, 2R-Cyclopentylmethyl-3-(formylhydroxyamino)-N-(1S-{4-[4-(2S-hydroxymethylpyrrolidine-1-carbonyl)phenoxy]piperidine-1-carbonyl}-2,2-dimethylpropyl)propionamide 325796-62-1P, 4-(1-{2S-[2R-Cyclopentylmethyl-3-(formylhydroxyamino)propionylamino]-3,3-dimethylbutyryl}piperidin-4-yloxy)benzoic acid methyl ester 325796-63-2P, 2R-Cyclopentylmethyl-3-(formylhydroxyamino)-N-(1S-[4-(4-hydroxymethylphenoxy) piperidine-1-carbonyl]-2,2-dimethylpropyl)propionamide.


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of hydroxamic acid and N-formyl hydroxylamine derivs. as antibacterial agents)

IT **325795-53-7P**, N-Hydroxy-N-[2R-(4-pyrimidin-2-yl)piperazine-1-carbonyl]hexyl]formamide **325795-54-8P**, N-[2R-[4-(4-Chlorophenyl)piperazine-1-carbonyl]hexyl]-N-hydroxyformamide
325795-55-9P, N-[2R-[4-Benzo(1,3)dioxol-5-ylmethyl)piperazine-1-carbonyl]hexyl]-N-hydroxyformamide **325795-56-0P**,
N-Hydroxy-N-[2R-[4-(4-methoxyphenyl)-3-methylpiperazine-1-carbonyl]hexyl]formamide **325795-57-1P**, N-[2R-[4-(4-Acetylphenyl)piperazine-1-carbonyl]hexyl]-N-hydroxyformamide
325795-58-2P, N-[2R-(4-Benzhydrylpiperazine-1-carbonyl)hexyl]-N-hydroxyformamide **325795-59-3P**, N-Hydroxy-N-[2R-(4-phenylpiperidine-1-carbonyl)hexyl]formamide **325795-60-6P**,
N-Hydroxy-N-[2R-[4-(hydroxydiphenylmethyl)piperidine-1-carbonyl]hexyl]formamide **325795-61-7P**, N-Hydroxy-N-[2R-(4-phenylpiperazine-1-carbonyl)hexyl]formamide **325795-62-8P**,
N-(2R-[4-(4-Chlorophenyl)phenylmethyl)piperazine-1-carbonyl]hexyl)-N-hydroxyformamide **325795-63-9P**, N-[2R-[4-(3-Chlorophenyl)piperazine-1-carbonyl]hexyl]-N-hydroxyformamide
325795-65-1P, N-Hydroxy-N-(2R-[4-[2-(2-hydroxyethoxy)ethyl)piperazine-1-carbonyl]hexyl)formamide
325795-67-3P, N-Hydroxy-N-[2R-[4-(3-hydroxypropyl)piperazine-1-carbonyl]hexyl]formamide **325795-68-4P**, N-Hydroxy-N-[2R-[2-(2-hydroxyethyl)piperazine-1-carbonyl]hexyl]formamide **325795-70-8P**,
N-(2R-[4-(3,4-Dichlorophenyl)piperazine-1-carbonyl]hexyl)-N-hydroxyformamide **325795-71-9P**, N-Hydroxy-N-[2R-[4-(4-methoxyphenyl)piperazine-1-carbonyl]hexyl]formamide **325795-72-0P**,
, N-Hydroxy-N-[2R-[4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carbonyl]hexyl]formamide **325795-73-1P**, N-Hydroxy-N-[2R-[4-(1H-indol-4-yl)piperazine-1-carbonyl]hexyl]formamide **325795-74-2P**,
N-(2R-[4-[Bis(4-fluorophenyl)methyl)piperazine-1-carbonyl]hexyl)-N-hydroxyformamide **325795-75-3P**, N-Hydroxy-N-[2R-[4-(4-nitrophenyl)piperazine-1-carbonyl]hexyl]formamide **325795-76-4P**,
N-[2R-[4-(4-Fluorophenyl)piperazine-1-carbonyl]hexyl]-N-hydroxyformamide
325795-77-5P, N-[2R-[4-(Furan-2-carbonyl)piperazine-1-carbonyl]hexyl]-N-hydroxyformamide **325795-78-6P**,
N-[2R-[4-(2,5-Dimethylphenyl)piperazine-1-carbonyl]hexyl]-N-hydroxyformamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hydroxamic acid and N-formyl hydroxylamine derivs. as antibacterial agents)

RN 325795-53-7 HCAPLUS
CN Piperazine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-54-8 HCAPLUS

CN Piperazine, 1-(4-chlorophenyl)-4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-55-9 HCAPLUS

CN Piperazine, 1-(1,3-benzodioxol-5-ylmethyl)-4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-56-0 HCAPLUS

CN Piperazine, 4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-1-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-57-1 HCPLUS

CN Piperazine, 1-(4-acetylphenyl)-4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-58-2 HCPLUS

CN Piperazine, 1-(diphenylmethyl)-4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-59-3 HCPLUS

CN Piperidine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-60-6 HCPLUS

CN 4-Piperidinemethanol, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-.alpha.,.alpha.-diphenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-61-7 HCPLUS

CN Piperazine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-62-8 HCPLUS

CN Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-63-9 HCPLUS

CN Piperazine, 1-(3-chlorophenyl)-4-[(2*R*)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-65-1 HCPLUS

CN Piperazine, 1-[(2*R*)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-[2-(2-hydroxyethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-67-3 HCPLUS

CN 1-Piperazinepropanol, 4-[(2*R*)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-68-4 HCAPLUS

CN 2-Piperazineethanol, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-70-8 HCAPLUS

CN Piperazine, 1-(3,4-dichlorophenyl)-4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-71-9 HCAPLUS

CN Piperazine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-72-0 HCAPLUS

CN Piperazine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-73-1 HCAPLUS

CN Piperazine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-(1H-indol-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-74-2 HCAPLUS

CN Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-75-3 HCPLUS

CN Piperazine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-76-4 HCPLUS

CN Piperazine, 1-(4-fluorophenyl)-4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-77-5 HCPLUS

CN Piperazine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-78-6 HCPLUS

CN Piperazine, 1-(2,5-dimethylphenyl)-4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 9 OF 20 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:64576 HCPLUS

DOCUMENT NUMBER: 134:249441

TITLE: Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor

AUTHOR(S): Clements, John M.; Beckett, R. Paul; Brown, Anthony; Catlin, Graham; Lobell, Mario; Palan, Shilpa; Thomas, Wayne; Whittaker, Mark; Wood, Stephen; Salama, Sameeh; Baker, Patrick J.; Rodgers, H. Fiona; Barynin, Vladimir; Rice, David W.; Hunter, Michael G.

CORPORATE SOURCE: British Biotech Pharmaceuticals Ltd., Oxford, OX4 6LY, UK

SOURCE: Antimicrobial Agents and Chemotherapy (2001), 45(2), 563-570

CODEN: AMACCQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Peptide deformylase (PDF) is an essential bacterial metalloenzyme which deformsylates the N-formylmethionine of newly synthesized polypeptides and

as such represents a novel target for antibacterial chemotherapy. To identify novel PDF inhibitors, we screened a metalloenzyme inhibitor library and identified an N-formyl-hydroxylamine deriv., BB-3497 (I, OHCN(OH)CH(Bu)CONHC(Bu-t)CONMe₂), and a related natural hydroxamic acid antibiotic, actinonin (II), as potent and selective inhibitors of PDF. To elucidate the interactions that contribute to the binding affinity of these inhibitors, we detd. the crystal structures of I and II bound to Escherichia coli PDF at resolns. of 2.1 and 1.75 .ANG., resp. In both complexes, the active-site metal atom was pentacoordinated by the side chains of Cys 90, His 132, and His 136 and the two oxygen atoms of N-formylhydroxylamine or hydroxamate. I had activity against gram-pos. bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis, and activity against some gram-neg. bacteria. Time-kill anal. showed that the mode of action of BB-3497 was primarily bacteriostatic. The mechanism of resistance was via mutations within the formyltransferase gene, as previously described for actinonin. While II and its derivs. have not been used clin. because of their poor pharmacokinetic properties, I was shown to be orally bioavailable. A single oral dose of I given 1 h after i.p. injection of S. aureus Smith or methicillin-resistant S. aureus protected mice from infection with median EDs of 8 and 14 mg/kg of body wt., resp. These data validate PDF as a novel target for the design of a new generation of antibacterial agents.

CC 10-5 (Microbial, Algal, and Fungal Biochemistry)

Section cross-reference(s): 1, 7, 75

IT **235784-88-0**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antibiotic activity and characterization of the novel peptide deformylase inhibitor BB-3497)

IT 9032-86-4D, Peptide deformylase, complexes with BB-3497 and actinonin
13434-13-4D, Actinonin, complexes with peptide deformylase

235784-88-0D, complexes with peptide deformylase

RL: PRP (Properties)

(crystal structure of)

IT **235784-88-0**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antibiotic activity and characterization of the novel peptide deformylase inhibitor BB-3497)

RN 235784-88-0 HCPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 235784-88-0D, complexes with peptide deformylase

RL: PRP (Properties)
(crystal structure of)

RN 235784-88-0 HCAPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:169388 HCAPLUS

DOCUMENT NUMBER: 132:208142

TITLE: Preparation of peptides as matrix metalloprotease inhibitors

INVENTOR(S): Castelhano, Arlindo Lucas; Bender, Steven Lee; Deal, Judith Gail; Horne, Stephen; Liak, Teng J.; Yuan, Zhengyu

PATENT ASSIGNEE(S): Syntex (U.S.A.) Inc., USA

SOURCE: U.S., 42 pp., Cont.-in-part of U.S. Ser. No. 147,811, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6037472	A	20000314	US 1994-343158	19941122
CA 2175667	AA	19950511	CA 1994-2175667	19941103

ZA 9408691	A	19960503	ZA 1994-8691	19941103
CN 1134153	A	19961023	CN 1994-194001	19941103
CN 1044249	B	19990721		
HU 74730	A2	19970228	HU 1996-1154	19941103
AT 155471	E	19970815	AT 1994-932023	19941103
ES 2105783	T3	19971016	ES 1994-932023	19941103
CZ 287642	B6	20010117	CZ 1996-1260	19941103
WO 9616027	A1	19960530	WO 1995-US15530	19951121
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9642897	A1	19960617	AU 1996-42897	19951121
AU 705439	B2	19990520		
EP 793643	A1	19970910	EP 1995-941493	19951121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9509802	A	19970930	BR 1995-9802	19951121
CN 1173170	A	19980211	CN 1995-197409	19951121
HU 77533	A2	19980528	HU 1997-1970	19951121
JP 10509719	T2	19980922	JP 1996-517109	19951121
RU 2163232	C2	20010220	RU 1997-110062	19951121
PL 182639	B1	20020228	PL 1995-321024	19951121
ZA 9509948	A	19970522	ZA 1995-9948	19951122
FI 9702160	A	19970522	FI 1997-2160	19970521
NO 9702307	A	19970722	NO 1997-2307	19970521
PRIORITY APPLN. INFO.:				
US 1993-147811 B2 19931104				
US 1994-343158 A 19941122				
WO 1995-US15530 W 19951121				

OTHER SOURCE(S): MARPAT 132:208142

AB Peptides R1CH2CH(XR2)CONHCHR3CONH(CH2)pR7 [R1 = SH, AcS, CO2H, hydroxycarbamoyl, N-hydroxyformamide, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, benzyloxycarbamoyl, or P(O)(OH)CH2SR6, where R6 = aryl, pyridyl, or thiazolyl; R2 = biphenyl; R3 = alkyl, cycloalkyl, aralkyl, alkylpyridyl, or alkylthiazolyl; R7 = 4-pyridyl or optionally substituted phenyl; p = 0; X = (CH2)^mY(CH2)ⁿ, where Y = O, S, or single bond, m, n = 0-4 (m + n = 0-4)] and their pharmaceutically acceptable salts were prep'd. The peptides inhibit matrix metalloproteases such as stromelysin, gelatinase, matrilysin and collagenase and are useful in the treatment of mammals having disease states alleviated by the inhibition of such matrix metalloproteases. Thus, N-[2R-[(tert-butoxycarbonyl)methyl]-5-(4-biphenyl)pentanoyl]-D(or L)-.beta.-hydroxyvaline-N'-phenylcarboxamide was prep'd. via coupling of DL-.beta.-hydroxyvaline-N'-phenylcarboxamide with the substituted pentanoic acid, with sepn. of the diastereomers by radial chromatog.

IC ICM C07D213-72

ICS C07D417-12

NCL 546269700

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 7

IT 1709-52-0P	25044-10-4P	112106-16-8P	112245-04-2P	156109-64-7P
168681-96-7P	169322-14-9P	169322-17-2P	169322-24-1P	169322-26-3P
169322-27-4P	169322-28-5P	169322-30-9P	169322-31-0P	169322-32-1P
169322-33-2P	169322-34-3P	169322-35-4P	169322-36-5P	179533-47-2P
179533-48-3P	179533-49-4P	179533-50-7P	179533-51-8P	
179533-52-9P	179533-53-0P	179533-54-1P	179533-55-2P	179533-56-3P

179533-57-4P	179533-58-5P	179533-59-6P	179533-60-9P	179533-61-0P
179533-62-1P	179533-63-2P	179533-64-3P	179533-65-4P	179533-66-5P
179533-74-5P	179533-78-9P	179533-79-0P	179533-80-3P	179533-81-4P
179533-82-5P	179533-83-6P	179533-84-7P	179533-85-8P	179533-86-9P
179533-87-0P	179533-88-1P	179533-89-2P	179533-90-5P	179533-92-7P
179534-15-7P	179797-41-2P	179797-42-3P	179797-43-4P	
179797-44-5P	179797-46-7P	179797-47-8P	179797-48-9P	179797-49-0P
179797-50-3P	179797-51-4P	179797-52-5P	179797-53-6P	179797-54-7P
179797-55-8P	179797-56-9P	179797-58-1P	179797-59-2P	179797-61-6P
179797-63-8P				


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of peptides as matrix metalloprotease inhibitors)

IT **179533-50-7P 179534-15-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of peptides as matrix metalloprotease inhibitors)

RN 179533-50-7 HCPLUS


CN Benzoic acid, 4-[[2-[(2-[(formylhydroxyamino)methyl]-4-methyl-1-oxopentyl]amino]-4-methyl-1-oxopentyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 179534-15-7 HCPLUS

CN L-Valinamide, (2R)-2-(3-[1,1'-biphenyl]-4-ylpropyl)-N-formyl-N-hydroxy-.beta.-alanyl-3-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 20 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:146885 HCPLUS



DOCUMENT NUMBER: 132:347877

TITLE: N-formyl hydroxylamine containing dipeptides:

generation of a new class of vasopeptidase inhibitors

AUTHOR(S): Robl, Jeffrey A.; Simpkins, Ligaya M.; Asaad, Magdi M.

CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(3), 257-260
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Four primary zinc-binding pharmacophores (thiols, carboxylates, phosphorus acids, and hydroxamates) were used to generate inhibitors of Zn metalloproteases such as ACE, NEP, the MMPs, and ECE. Although compds. which inhibit the activity of both ACE and NEP (vasopeptidase inhibitors, VPIs) have been reported which incorporate a thiol, carboxylate, or phosphorus acid pharmacophore, the generation of hydroxamate based vasopeptidase inhibitors has remained elusive. The first potent vasopeptidase inhibitors, which were generated from the incorporation of conformationally restricted dipeptide mimetics to an N-formyl hydroxylamine Zn-binding group, have been prep'd. Compds. such as the aminobenzopyridoazepincarboxylate I and the aminobenzazepincarboxylate II are among the most potent in this series, exhibiting in vitro activity comparable to other classes of inhibitors.

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 27, 28

IT 197902-84-4P 197902-85-5P 269396-29-4P **269396-31-8P**
 269396-33-0P 269396-34-1P 269408-26-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of vasopeptidase-inhibiting, heterocyclic, conformationally-restricted dipeptide mimetics contg. N-formylhydroxylamine amino acids)

IT **269396-31-8P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of vasopeptidase-inhibiting, heterocyclic, conformationally-restricted dipeptide mimetics contg. N-formylhydroxylamine amino acids)

RN 269396-31-8 HCAPLUS

CN L-Phenylalanine, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:84604 HCAPLUS

DOCUMENT NUMBER: 132:141951

TITLE: Pharmaceutical compositions containing ACAT and MMP inhibitors for the treatment of atherosclerotic lesions

INVENTOR(S): Bocan, Thomas Michael Andrew

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004892	A2	20000203	WO 1999-US13948	19990618
WO 2000004892	A3	20000518		
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335062	AA	20000203	CA 1999-2335062	19990618
AU 9947017	A1	20000214	AU 1999-47017	19990618
BR 9912296	A	20010417	BR 1999-12296	19990618
EP 1098662	A2	20010516	EP 1999-930483	19990618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 200100046	A	20020617	EE 2001-46	19990618
JP 2002521328	T2	20020716	JP 2000-560885	19990618
BG 105162	A	20011231	BG 2001-105162	20010117
NO 2001000291	A	20010118	NO 2001-291	20010118

PRIORITY APPLN. INFO.:

US 1998-93639P P 19980721
WO 1999-US13948 W 19990618

AB Acyl-CoA:cholesterol acyltransferase (ACAT) and matrix metalloproteinase (MMP) inhibitors are coadministered for the redn. of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal. The direct antiatherosclerotic potential of the combination of ACAT inhibitor, [[2,4,6-tris-(1-methyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl sulfamic acid, and the HMG-CoA reductase inhibitor, simavastatin, in rabbits was studied. A tablet contained 2-(4'-bromobiphenyl-4-sulfonylamino)-3-Me butyric acid 25 ACAT compd. lactose 50, corn starch 20, and magnesium stearate 5 mg.

IC ICM A61K031-00

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

IT	256644-29-8	256644-30-1	256644-31-2	256644-32-3	256644-33-4
	256644-34-5	256644-35-6	256644-36-7	256644-37-8	256644-38-9
	256644-39-0	256644-40-3	256644-41-4	256644-42-5	256644-43-6
	256644-44-7	256644-45-8	256644-46-9	256644-47-0	256644-48-1
	256644-49-2	256644-50-5	256644-51-6	256644-52-7	256644-53-8
	256644-54-9	256644-55-0	256644-56-1	256644-57-2	256644-58-3
	256644-59-4	256644-60-7	256644-61-8	256644-62-9	256644-63-0
	256644-64-1	256644-65-2	256644-66-3	256644-67-4	256644-68-5
	256644-69-6	256644-70-9	256644-71-0	256644-72-1	256644-73-2
	256644-74-3	256644-75-4	256644-76-5	256644-77-6	256644-78-7
	256644-79-8	256644-80-1	256644-82-3	256644-83-4	256644-84-5
	256644-85-6	256644-86-7	256644-87-8	256644-88-9	256644-89-0
	256644-90-3	256644-91-4	256644-92-5	256644-93-6	256644-94-7
	256644-95-8	256644-96-9	256644-97-0	256644-98-1	256644-99-2
	256645-00-8	256645-01-9	256645-02-0	256645-03-1	256645-04-2
	256645-05-3	256645-06-4	256645-07-5	256645-08-6	
	256645-09-7	256645-10-0	256645-11-1	256645-12-2	256645-13-3
	256645-14-4	256645-15-5	256645-16-6	256645-17-7	256645-18-8
	256645-19-9	256645-20-2	256645-21-3	256645-22-4	256645-23-5
	256645-24-6	256645-25-7	256645-26-8	256645-27-9	256645-28-0
	256645-29-1	256645-30-4	256645-31-5	256645-32-6	256645-33-7
	256645-34-8	256645-35-9	256645-36-0	256645-37-1	256645-38-2
	256645-39-3	256645-40-6	256645-41-7	256645-42-8	
	256645-43-9	256645-44-0	256645-45-1	256645-46-2	256645-47-3
	256645-48-4	256645-49-5	256645-50-8	256645-51-9	256645-52-0
	256645-53-1	256645-54-2	256645-55-3	256645-56-4	256645-57-5
	256645-58-6	256645-59-7	256645-60-0	256645-61-1	256645-62-2
	256645-63-3	256645-64-4	256645-65-5	256645-66-6	256645-67-7
	256645-68-8	256645-69-9	256645-70-2	256645-71-3	256645-72-4
	256645-73-5	256645-74-6	256645-75-7	256645-76-8	256645-77-9
	256645-78-0	256645-79-1	256645-80-4	256645-81-5	256645-82-6
	256645-83-7	256645-84-8	256645-85-9	256645-86-0	256645-87-1
	256645-88-2	256645-89-3	256645-91-7	256645-93-9	256645-94-0
	256645-95-1	256645-96-2	256645-97-3	256645-98-4	256645-99-5
	256646-00-1	256646-01-2	256646-02-3	256646-03-4	256646-04-5
	256646-05-6	256646-06-7	256646-07-8	256646-08-9	256646-09-0
	256646-10-3	256646-11-4	256646-12-5	256646-13-6	256646-14-7
	256646-15-8	256646-16-9	256646-17-0	256646-18-1	256646-19-2
	256646-20-5	256646-21-6	256646-22-7	256646-23-8	256646-24-9
	256646-25-0	256646-26-1	256646-27-2	256646-28-3	256646-29-4
	256646-30-7	256646-31-8	256646-32-9	256646-33-0	256646-34-1
	256646-35-2	256646-36-3	256646-37-4	256646-38-5	256646-39-6

256646-40-9	256646-41-0	256646-42-1	256646-43-2	256646-44-3
256646-45-4	256646-46-5	256646-47-6	256646-48-7	256646-49-8
256646-50-1	256646-51-2	256646-52-3	256646-53-4	256646-54-5
256646-55-6	256646-56-7	256646-57-8	256646-58-9	256646-59-0
256646-60-3	256646-61-4	256646-62-5	256646-63-6	256646-64-7
256646-66-9	256646-68-1	256646-69-2		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. contg. ACAT and MMP inhibitors for treatment of atherosclerotic lesions)


IT 256645-06-4 256645-41-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. contg. ACAT and MMP inhibitors for treatment of atherosclerotic lesions)

RN 256645-06-4 HCPLUS


CN Valinamide, 2-(3-[1,1'-biphenyl]-4-ylpropyl)-N-formyl-N-hydroxy-.beta.-alanyl-3-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 256645-41-7 HCPLUS

CN Leucinamide, 2-(3-[1,1'-biphenyl]-4-ylpropyl)-N-formyl-N-hydroxy-.beta.-alanyl-N-[4-[[2-(dimethylamino)ethyl]amino]sulfonylphenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— NMe₂

L8 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:511017 HCAPLUS
 DOCUMENT NUMBER: 131:144852
 TITLE: Preparation of N-formylhydroxylamine-containing peptidyl compounds as antibacterial agents
 INVENTOR(S): Hunter, Michael George; Beckett, Raymond Paul; Clements, John Martin; Whittaker, Mark; Davies, Stephen John; Pratt, Lisa Marie; Spavold, Zoe Marie; Launchbury, Steven
 PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Limited, UK
 SOURCE: PCT Int. Appl., 136 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9939704	A1	19990812	WO 1999-GB386	19990205
W: AU, BR, CA, CN, CZ, GB, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2320476	AA	19990812	CA 1999-2320476	19990205
AU 9925292	A1	19990823	AU 1999-25292	19990205
AU 749699	B2	20020704		
BR 9907689	A	20001114	BR 1999-7689	19990205
GB 2349884	A1	20001115	GB 2000-16855	19990205
EP 1052984	A1	20001122	EP 1999-904977	19990205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002502815	T2	20020129	JP 2000-530203	19990205
NZ 505675	A	20021126	NZ 1999-505675	19990205
ZA 9902045	A	20001011	ZA 1999-2045	19990312
US 6423690	B1	20020723	US 2000-355489	20000107
NO 2000003969	A	20000928	NO 2000-3969	20000804
US 2002165167	A1	20021107	US 2002-134754	20020430
PRIORITY APPLN. INFO.:				
		GB 1998-2549	A	19980207
		GB 1998-6300	A	19980324
		GB 1998-10463	A	19980516
		GB 1998-28318	A	19981222
		WO 1999-GB386	W	19990205
		US 2000-355489	A3	20000107

OTHER SOURCE(S): MARPAT 131:144852
 AB Title compds. OCHN(OH)CHR1CHR2COA [R1 = H, alkyl, haloalkyl; R2 =

R₁₀(X)_n(ALK)m-, where R₁₀ = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclyl; ALK = alkylene, alkenylene, alkynylene which may be interrupted by one or more nonadjacent NH, O, or S linkages; X = NH, O, S; m, n = 0 or 1; A = NR₃CHR₄CONR₅R₆, NR₃CHR₄CO₂H, NR₃CHR₄CH₂OR₇, or NR₅R₆, where R₃ = H, R₄ is a side chain of natural or non-natural .alpha.-amino acid or R₃ and R₄ form a ring; R₅, R₆ = H, (un)substituted alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl or R₅ and R₆ form a ring; R₇ = H, alkyl, acyl] were prepd. as antibacterial agents. Thus, 2R(or S)-[(formylhydroxyamino)methyl]hexanoic acid (2,2-dimethyl-1S-methylcarbamoylpropyl)amide, prepd. via reactions of butylmalonic acid and tert-leucine N-methylamide, showed min. inhibitory concn. 12.5 .mu.M against E coli DH5.alpha., vs. 25 .mu.M for carbenicillin.

ICM A61K031-16
ICS A61K031-535; A61K031-165; A61K031-44; A61K031-40; A61K031-195;
A61K031-47; A61K031-495; A61K031-445; A61K031-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 10

IT 235784-75-5P 235784-76-6P 235784-77-7P
235784-79-9P 235784-80-2P 235784-81-3P 235784-82-4P
235784-83-5P 235784-84-6P 235784-85-7P
235784-86-8P 235784-87-9P 235784-88-0P
235784-89-1P 235784-90-4P 235784-91-5P
235784-93-7P 235784-94-8P 235784-95-9P
235784-96-0P 235784-97-1P 235784-98-2P
235784-99-3P 235785-00-9P 235785-02-1P
235785-03-2P 235785-04-3P 235785-05-4P 235785-06-5P
235785-07-6P 235785-08-7P 235785-09-8P
235785-10-1P 235785-11-2P 235785-12-3P
235785-14-5P 235785-15-6P 235785-16-7P
235785-17-8P 235785-18-9P 235785-19-0P
235785-20-3P 235785-21-4P 235785-22-5P
235785-24-7P 235785-25-8P 235785-26-9P 235785-27-0P
235785-28-1P 235785-29-2P 235785-31-6P 235785-32-7P
235785-33-8P 235785-34-9P 235785-35-0P 235785-36-1P
235785-38-3P 235785-40-7P 235785-42-9P 235785-45-2P
235785-46-3P 235785-48-5P 235785-50-9P
235785-52-1P 235785-54-3P 235785-56-5P 235785-58-7P
235785-60-1P 235785-63-4P 235785-64-5P
235785-66-7P 235785-67-8P 235785-68-9P
235785-69-0P 235785-70-3P 235785-72-5P
235785-73-6P 235785-74-7P 235785-75-8P
235785-76-9P 235785-77-0P 235785-78-1P 235785-79-2P
235785-80-5P 235785-82-7P 235785-83-8P
235785-84-9P 235785-85-0P 235785-86-1P
235785-87-2P 235785-88-3P 235785-89-4P 235785-90-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-formylhydroxylamine-contg. peptidyl compds. as antibacterial agents)

IT 235784-75-5P 235784-76-6P 235784-79-9P
235784-82-4P 235784-83-5P 235784-84-6P
235784-85-7P 235784-87-9P 235784-88-0P
235784-89-1P 235784-90-4P 235784-91-5P
235784-93-7P 235784-94-8P 235784-96-0P
235784-97-1P 235784-98-2P 235784-99-3P
235785-00-9P 235785-02-1P 235785-03-2P


235785-04-3P 235785-08-7P 235785-09-8P
 235785-10-1P 235785-11-2P 235785-12-3P
 235785-14-5P 235785-15-6P 235785-16-7P
 235785-17-8P 235785-18-9P 235785-20-3P
 235785-21-4P 235785-22-5P 235785-24-7P
 235785-25-8P 235785-29-2P 235785-35-0P
 235785-46-3P 235785-48-5P 235785-50-9P
 235785-56-5P 235785-58-7P 235785-60-1P
 235785-64-5P 235785-66-7P 235785-67-8P
 235785-68-9P 235785-69-0P 235785-70-3P
 235785-72-5P 235785-73-6P 235785-74-7P
 235785-76-9P 235785-79-2P 235785-80-5P
 235785-82-7P 235785-83-8P 235785-84-9P
 235785-85-0P 235785-86-1P 235785-88-3P
235785-89-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-formylhydroxylamine-contg. peptidyl compds. as antibacterial agents)

RN 235784-75-5 HCAPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,3-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-76-6 HCAPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(1,1-dimethylethyl)-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235784-79-9 HCAPLUS

CN L-Alaninamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-82-4 HCAPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-3-methyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-83-5 HCAPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-84-6 HCAPLUS


CN L-Phenylalaninamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235784-85-7 HCPLUS
 CN L-Leucinamide, 2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235784-87-9 HCPLUS
 CN L-Prolinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235784-88-0 HCPLUS
 CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-89-1 HCAPLUS

CN L-Valinamide, (2R)-2-(cyclopentylmethyl)-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-90-4 HCAPLUS

CN L-Valinamide, (2R)-N-formyl-N-hydroxy-2-pentyl-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-91-5 HCAPLUS

CN L-Valinamide, N-formyl-N-hydroxy-2-propyl-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-93-7 HCPLUS

CN L-Valinamide, N-formyl-N-hydroxy-2-(2-methylpropyl)-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-94-8 HCPLUS

CN L-Valinamide, 2-(cyclohexylmethyl)-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-96-0 HCPLUS

CN L-Valinamide, N-formyl-2-hexyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-97-1 HCPLUS

CN L-Valinamide, N-formyl-2-heptyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-98-2 HCPLUS

CN L-Valinamide, N-formyl-N-hydroxy-2-octyl-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235784-99-3 HCPLUS

CN L-Valinamide, N-formyl-N-hydroxy-2-(3-methylbutyl)-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-00-9 HCPLUS

CN L-Valinamide, (2R)-N-formyl-N-hydroxy-2-methyl-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-02-1 HCPLUS

CN L-Valinamide, N-formyl-N-hydroxy-2-(1-methylethyl)-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-03-2 HCPLUS

CN L-Valinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-04-3 HCAPLUS

CN L-Valinamide, N-formyl-N-hydroxy-2-[(4-methoxyphenyl)methyl]-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-08-7 HCAPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-(2-hydroxyethyl)-N,3-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-09-8 HCAPLUS

CN D-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-10-1 HCAPLUS

CN L-Isoleucinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-11-2 HCAPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-3-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-12-3 HCAPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-3-hydroxy-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-14-5 HCPLUS

CN L-Phenylalaninamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-4-chloro-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-15-6 HCPLUS

CN L-Tyrosinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-16-7 HCPLUS

CN L-Alaninamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-17-8 HCAPLUS

CN L-Alaninamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-3-cyclohexyl-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-18-9 HCAPLUS

CN Glycinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-20-3 HCAPLUS

CN L-Lysinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-21-4 HCPLUS

CN L-Serinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-22-5 HCPLUS

CN Piperazine, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-24-7 HCPLUS

CN Morpholine, 4-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-25-8 HCPLUS

CN 2-Pyrrolidinemethanol, 1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl] - , (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-29-2 HCPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-3-methyl-N-(2-phenylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-35-0 HCPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N-cyclohexyl-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-46-3 HCPLUS

CN 1-Piperidinopropanamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2,2-dimethylpropyl]-.alpha.-[(formylhydroxyamino)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-48-5 HCPLUS

CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl-3-(methylthio)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-50-9 HCPLUS


CN L-Valinamide, (2R)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl-3-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235785-56-5 HCAPLUS
 CN L-Valinamide, (2R)-N-formyl-N-hydroxy-2-(2-propenyl)-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235785-58-7 HCAPLUS
 CN L-Valinamide, (2R)-2-(3-but enyl)-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235785-60-1 HCAPLUS
 CN L-Valinamide, (2R)-2-(2-butynyl)-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 235785-64-5 HCAPLUS
 CN Valinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-N-cyclohexyl-3-methyl- (9CI) (CA INDEX NAME)



RN 235785-66-7 HCAPLUS
 CN Norleucinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-N-cyclohexyl-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 235785-67-8 HCAPLUS
 CN Norleucinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-3,3-dimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 235785-68-9 HCAPLUS

CN Valinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-N-(1,1-dimethylethyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 235785-69-0 HCAPLUS

CN Norleucinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-3,3-dimethyl-N-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




RN 235785-70-3 HCAPLUS

CN Glycinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-N,2-dicyclohexyl- (9CI) (CA INDEX NAME)




RN 235785-72-5 HCAPLUS

CN Glycinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-2-cyclohexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 235785-73-6 HCAPLUS


CN Glycinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-2-cyclohexyl-N-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)



RN 235785-74-7 HCPLUS

CN L-Valinamide, (2S)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,3-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-76-9 HCPLUS

CN L-Alaninamide, (2S)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-79-2 HCPLUS


CN L-Valinamide, (2S)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-3-methyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235785-80-5 HCAPLUS
 CN L-Phenylalaninamide, (2S)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235785-82-7 HCAPLUS
 CN L-Prolinamide, (2S)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235785-83-8 HCAPLUS
 CN L-Valinamide, (2S)-2-butyl-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-84-9 HCPLUS

CN L-Valinamide, (2S)-2-(cyclopentylmethyl)-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-85-0 HCPLUS

CN L-Valinamide, (2S)-N-formyl-N-hydroxy-2-pentyl-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-86-1 HCPLUS

CN L-Valinamide, (2S)-N-formyl-N-hydroxy-2-methyl-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-88-3 HCAPLUS

CN L-Valinamide, (2S)-2-(3-butenyl)-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235785-89-4 HCAPLUS

CN L-Valinamide, (2S)-2-(2-butynyl)-N-formyl-N-hydroxy-.beta.-alanyl-N,N,3-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:476742 HCAPLUS

DOCUMENT NUMBER: 125:143320

TITLE: Prepn. of peptides as matrix metalloprotease inhibitors

INVENTOR(S): Castelhano, Arlindo L.; Bender, Steven L.; Deal, Judith G.; Horne, Stephen; Liak, Teng J.; Yuan,

Zhengyu

PATENT ASSIGNEE(S): Syntex (U.S.A.) Inc., USA; Agouron Pharmaceuticals,

Inc.

SOURCE: PCT Int. Appl., 152 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616027	A1	19960530	WO 1995-US15530	19951121
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6037472	A	20000314	US 1994-343158	19941122
AU 9642897	A1	19960617	AU 1996-42897	19951121
AU 705439	B2	19990520		
EP 793643	A1	19970910	EP 1995-941493	19951121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9509802	A	19970930	BR 1995-9802	19951121
JP 10509719	T2	19980922	JP 1996-517109	19951121
RU 2163232	C2	20010220	RU 1997-110062	19951121
PL 182639	B1	20020228	PL 1995-321024	19951121
FI 9702160	A	19970522	FI 1997-2160	19970521
NO 9702307	A	19970722	NO 1997-2307	19970521
PRIORITY APPLN. INFO.:			US 1994-343158 A	19941122
			US 1993-147811 B2	19931104
			WO 1995-US15530 W	19951121

OTHER SOURCE(S): MARPAT 125:143320

AB Peptides R1CH2CH(XR2)CONHCHR3C(=O)NR4(R5) [R1 = SH, AcS, CO2H, etc.; R2 = alkyl, cycloalkyl, aryl, heterocycloalkyl, heteroaryl; R3 = alkyl, cycloalkyl, aralkyl, heteroaralkyl; R7 = aryl, heteroaryl, heterocycloalkyl; p = 0-4; X = (CH2)mY(CH2)n, where Y = O, S, or single bond, m, n = 0-4 (m + n = 0-4)] and their pharmaceutically acceptable salts were prep'd. The peptides inhibit matrix metalloproteases such as stromelysin, gelatinase, matrilysin and collagenase and are useful in the treatment of mammals having disease states alleviated by the inhibition of such matrix metalloproteases. Thus, N-[2R-[(tert-butoxycarbonyl)methyl]-5-(4-biphenyl)pentanoyl]-D(or L)-.beta.-hydroxyvaline-N'-phenylcarboxamide was prep'd. via coupling of DL-.beta.-hydroxyvaline-N'-phenylcarboxamide with the substituted pentanoic acid, with sepn. of the diastereomers by radial chromatog.

IC ICM C07C259-06

ICS C07C237-22; C07F009-60; C07C327-30; C07C323-60; C07D263-26;
A61K031-16; A61K031-66

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 7, 63

IT 1709-52-0P	25044-10-4P	112106-16-8P	112245-04-2P	156109-64-7P
168681-96-7P	169322-14-9P	169322-17-2P	169322-24-1P	169322-26-3P
169322-27-4P	169322-28-5P	169322-30-9P	169322-31-0P	169322-32-1P
169322-33-2P	169322-34-3P	169322-35-4P	169322-36-5P	179533-47-2P
179533-48-3P	179533-49-4P	179533-50-7P	179533-51-8P	

179533-52-9P	179533-53-0P	179533-54-1P	179533-55-2P	179533-56-3P
179533-57-4P	179533-58-5P	179533-59-6P	179533-60-9P	179533-61-0P
179533-62-1P	179533-63-2P	179533-64-3P	179533-65-4P	179533-66-5P
179533-74-5P	179533-78-9P	179533-79-0P	179533-80-3P	179533-81-4P
179533-82-5P	179533-83-6P	179533-84-7P	179533-85-8P	179533-86-9P
179533-87-0P	179533-88-1P	179533-89-2P	179533-90-5P	179533-92-7P
179534-15-7P	179797-41-2P	179797-42-3P	179797-43-4P	
179797-44-5P	179797-46-7P	179797-47-8P	179797-48-9P	179797-49-0P
179797-50-3P	179797-51-4P	179797-52-5P	179797-53-6P	179797-54-7P
179797-55-8P	179797-56-9P	179797-58-1P	179797-59-2P	179797-61-6P
179797-63-8P				


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of peptides as matrix metalloprotease inhibitors)

IT 179533-50-7P 179534-15-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of peptides as matrix metalloprotease inhibitors)

RN 179533-50-7 HCAPLUS


CN Benzoic acid, 4-[[2-[(2-[(formylhydroxyamino)methyl]-4-methyl-1-oxopentyl]amino)-4-methyl-1-oxopentyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 179534-15-7 HCAPLUS

CN L-Valinamide, (2R)-2-(3-[1,1'-biphenyl]-4-ylpropyl)-N-formyl-N-hydroxy-beta.-alanyl-3-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:175615 HCAPLUS

DOCUMENT NUMBER: 124:233142

TITLE: Preparation of N-(2-carboxymethyalkanoyl) amino acid amides and analogs as metalloprotease inhibitors


INVENTOR(S): Miller, Andrew; Beckett, Paul Raymond; Martin, Fionna Mitchell; Whittaker, Mark

PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Ltd., UK
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9532944	A1	19951207	WO 1995-GB1226	19950526
W: AU, BR, CA, CN, CZ, DE, FI, GB, HU, JP, KR, NO, NZ, PL, RU, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9525722	A1	19951221	AU 1995-25722	19950526
EP 763012	A1	19970319	EP 1995-920160	19950526
EP 763012	B1	19990609		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
JP 10500986	T2	19980127	JP 1995-500504	19950526
AT 181055	E	19990615	AT 1995-920160	19950526
US 6028110	A	20000222	US 1996-737981	19961122
PRIORITY APPLN. INFO.:			GB 1994-10802	19940528
			GB 1995-3754	19950224
			WO 1995-GB1226	19950526

OTHER SOURCE(S): MARPAT 124:233142

GI



AB R1CHRCHR2CONHCHR3CONR4R5 [R = CO2H, N(OH)CHO, CONHOH; R1 = H, alkyl, Ph, heterocycll, etc.; R2 = (heteroatom interrupted) C13-24 hydrocarbon chain; R3 = amino acid side chain; R4 = H, (un)substituted alkyl; R5 = H or alkyl] were prep'd. Thus, (R)-HO2CCHR2CH2CO2CMe3 (R2 = hexadecyl) was esterified by pentafluorophenol and the product amidated by L-H2NCH(CH2Ph)CONHMe to give, after deprotection, title compd. I (R2 = hexadecyl) which had IC50 of 30nM against gelatinase in vitro.

IC ICM C07C237-22

ICS C07C323-60; C07C259-06; A61K031-16

CC 34-2 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1

IT 174611-14-4P 174611-15-5P 174611-16-6P 174611-17-7P 174611-19-9P
 174611-21-3P 174611-22-4P 174611-23-5P 174611-24-6P 174611-25-7P
 174611-26-8P 174611-27-9P 174611-28-0P 174611-29-1P 174611-30-4P
 174611-31-5P 174611-32-6P 174611-33-7P 174611-34-8P 174611-35-9P
174611-36-0P 174611-37-1P 174611-38-2P 174691-79-3P
174691-80-6P 174691-82-8P 174691-83-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-(2-carboxymethyalkanoyl) amino acid amides and analog

metalloprotease inhibitors)


IT 174611-36-0P 174691-80-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-(2-carboxymethyalkanoyl) amino acid amides and analogs as metalloprotease inhibitors)

RN 174611-36-0 HCPLUS

CN Octadecanamide, N-[2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-2-[(formylhydroxyamino)methyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174691-80-6 HCPLUS

CN Octadecanamide, N-[2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-2-[(formylhydroxyamino)methyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 16 OF 20 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:19442 HCPLUS

DOCUMENT NUMBER: 122:230797

TITLE: Inhibition of tumor necrosis factor (TNF) production

INVENTOR(S): Crimmin, Michael John; Galloway, William Alan;

Gearing, Andrew John Hubert

PATENT ASSIGNEE(S): British Bio-Technology Ltd., UK

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9410990	A1	19940526	WO 1993-GB2331	19931112
W: AU, CA, DE, ES, FI, GB, JP, KR, NO, NZ, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9454301	A1	19940608	AU 1994-54301	19931112
EP 667770	A1	19950823	EP 1993-924754	19931112
EP 667770	B1	19970319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08505605	T2	19960618	JP 1993-511862	19931112
AT 150300	E	19970415	AT 1993-924754	19931112
ES 2101358	T3	19970701	ES 1993-924754	19931112
US 5691382	A	19971125	US 1995-436190	19950512
PRIORITY APPLN. INFO.:			GB 1992-23904	19921113
			WO 1993-GB2331	19931112

AB Certain hydroxamic acid derivs., previously known as inhibitors of matrix metalloproteinases (e.g. collagenase) are capable of inhibiting the prodn. of TNF by cells, and thus are useful in the management of diseases or conditions mediated by overprodn. of, or over-responsiveness to, TNF. The compds. in question are known in the art from the following patent publications: US 4599361, EP-A-0236872, EP-A-0274453, WO 90/05716, WO 90/05719, WO 91/02716, EP-A-0489577, EP-A-0489579, EP-A-0497192, WO 92/13831, WO 92/22523, WO 93/09090, and WO 93/09097. They have general formula $\text{CH}(\text{R}1)(\text{CONHOH})\text{CH}(\text{R}2)\text{C}(\text{O})\text{NHCH}(\text{R}3)\text{C}(\text{O})\text{N}(\text{R}4)(\text{R}5)$ or $\text{CH}(\text{R}1)[\text{N}(\text{OH})(\text{CO})\text{H}]\text{CH}(\text{R}2)\text{C}(\text{O})\text{NHCH}(\text{R}3)\text{C}(\text{O})\text{N}(\text{R}4)(\text{R}5)$, in which substituents R1-R5 may vary widely according to the disclosures of those patent publications. Prevention of e.g. TNF release from phorbol myristate acetate-stimulated human monocytic cell line U937 by compds. of the invention is described.

ICM A61K031-16

CC 1-12 (Pharmacology)

IT 104408-38-0	104485-71-4	104485-72-5	108383-58-0	112105-57-4
130128-24-4	130128-25-5	130128-37-9	130128-40-4	130128-54-0
130194-41-1	130195-95-8	130370-59-1	130370-60-4	130370-64-8
130370-65-9	130370-66-0	130370-67-1	130370-71-7	130370-72-8
130370-73-9	130370-74-0	130370-76-2	130370-78-4	132159-80-9
135775-01-8	135775-04-1	144287-57-0	144287-59-2	144287-60-5
144287-61-6	144287-68-3	144287-69-4	144287-80-9	144287-81-0
145337-55-9	153491-08-8	153491-09-9	153491-10-2	153491-11-3
153491-12-4	153491-14-6	153491-15-7	153491-16-8	153491-17-9
153491-18-0	153491-21-5	153547-33-2	155832-36-3	155832-40-9
155832-43-2	155865-40-0	157518-67-7	157725-86-5	157725-87-6
157725-88-7	157725-89-8	157725-90-1	157725-91-2	157725-92-3
157725-93-4	157725-94-5	157725-95-6	157725-96-7	157725-97-8
157725-98-9	157725-99-0	157726-00-6	157726-01-7	157726-02-8
157726-03-9	157726-04-0	157726-05-1	157726-06-2	157726-07-3
157726-08-4	157726-09-5	157726-10-8	157726-11-9	157726-12-0
157726-13-1	157726-14-2	157726-15-3	157726-16-4	157726-17-5
157726-18-6	157726-19-7	157726-20-0	157726-21-1	
157726-22-2	157726-23-3	157726-24-4	157726-25-5	157726-26-6
157726-27-7	157726-28-8	157726-29-9	157726-30-2	157726-31-3
157726-32-4	157809-68-2	157809-69-3	157809-70-6	157809-71-7
157809-72-8	157809-73-9	157809-74-0	157809-75-1	157809-76-2

157870-74-1

RL: BIOL (Biological study)
(TNF prodn. inhibition by)


IT **157726-20-0**

RL: BIOL (Biological study)

(TNF prodn. inhibition by)

RN 157726-20-0 HCAPLUS

CN Benzenepropanamide, .alpha.-[[2-[(formylhydroxyamino)methyl]-4-methyl-1-oxopentyl]amino]-4-methoxy-N-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1994:426909 HCAPLUS
 DOCUMENT NUMBER: 121:26909
 TITLE: Vasoactive peptide inhibition
 INVENTOR(S): Crimmin, Michael John; Bone, Elisabeth Ann; Wood, Lars
 Michael
 PATENT ASSIGNEE(S): British Bio-Technology Ltd., UK
 SOURCE: PCT Int. Appl., 15 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407527	A2	19940414	WO 1993-GB2044	19931001
WO 9407527	A3	19940721		
		W: AU, CA, FI, GB, JP, KR, NO, NZ, PT, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE		
AU 9348316	A1	19940426	AU 1993-48316	19931001
PRIORITY APPLN. INFO.:			GB 1992-20845	A 19921003
			WO 1993-GB2044	W 19931001

AB Certain known hydroxamic acid derivs. and their salts are useful as inhibitors of the conversion of big endothelin (I) to endothelin by a putative endothelin converting enzyme, and are useful in the management of diseases mediated by overprodn. of, over-responsiveness to, endothelin in mammals, e.g. hypertension. Thus, i.v. administration of 1mg [4-(N-hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine/kg in rats 5 min before i.v. administration of I inhibited its activity by 62%.

ICM A61K037-64


CC 1-8 (Pharmacology)

IT 92175-57-0	104408-38-0	104485-71-4	108383-57-9	108383-58-0
130128-25-5	132159-77-4	144287-54-7	144287-57-0	144287-58-1
144287-61-6	144287-68-3	144287-74-1	144287-79-6	144287-80-9
144287-81-0	155832-36-3	155832-37-4	155832-38-5	
155832-39-6	155832-40-9	155832-41-0	155832-42-1	155832-43-2
155832-44-3	155832-45-4	155832-46-5	155865-40-0	

RL: BIOL (Biological study)

IT 155832-37-4
 RL: BIOL (Biological study)
 (as inhibitor of big endothelin conversion to endothelin)
 RN 155832-37-4 HCAPLUS
 CN Benzenepropanamide, .alpha.-[[2-[(formylhydroxyamino)methyl]-4-methyl-1-oxopentyl]amino]-4-methoxy-N-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1988:167973 HCAPLUS
 DOCUMENT NUMBER: 108:167973
 TITLE: Preparation of (hydroxylamino)acylpeptides as inhibitors of synovial collagenase
 INVENTOR(S): Handa, Balraj Krishnan; Johnson, William Henry; Machin, Peter James
 PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 236872	A2	19870916	EP 1987-102771	19870226
EP 236872	A3	19890913		
EP 236872	B1	19921125		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
DK 8700774	A	19870912	DK 1987-774	19870216
AT 82753	E	19921215	AT 1987-102771	19870226
CA 1314655	A1	19930316	CA 1987-530988	19870303
ZA 8701563	A	19871028	ZA 1987-1563	19870304
IL 81790	A1	19910310	IL 1987-81790	19870305
AU 8769902	A1	19870917	AU 1987-69902	19870311
AU 588437	B2	19890914		
JP 62230757	A2	19871009	JP 1987-56412	19870311
JP 06029228	B4	19940420		
US 4996358	A	19910226	US 1989-336264	19890411
PRIORITY APPLN. INFO.:				
		GB 1986-5977	19860311	
		GB 1986-29712	19861212	
		US 1987-14957	19870217	
		EP 1987-102771	19870226	

AB ACHR3CHR1CONHCHR2CONR6CHR4R5 [I; A = HN(OH)CO, HCON(OH); R1 = alkyl; R2 = side chain of naturally-occurring amino acid, not H, Me; R2R4 = (CH₂)_n; R3 = H, amino, OH, SH, alkyl, alkoxy, alkylthio, arylalkyl, etc.; R4, R6 = H, Me; R5 = H, R4R5 = (CH₂)₃; alkyl, alkoxyalkyl, dialkoxymethylene, carboxy, acyl, carbamoyl; n = 4-11] and pharm. acceptable salts were prep'd. for treatment of degenerative joint disease. [2(R)-Isobutylysuccinyl]-L-leucyl-L-alanine Et ester (prepn. given) in THF at -15.degree. was treated with iso-Bu chloroformate and N-ethylmorpholine followed by O-benzylhydroxylamine. The resulting benzylxyamino deriv. was hydrogenolyzed in EtOH over 5% Pd/C to give 4-N-hydroxylaminol-2(R)-isobutylysuccinyl]-L-leucyl-L-alanine Et ester. The latter inhibited human synovial collagenase with an IC₅₀ of 8.5 times 10⁻⁹ M.

IC ICM C07K005-06

ICS C07C103-50; A61K037-02; C07C103-76; A61K031-16

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1

IT	112105-53-0P	112105-54-1P	112105-55-2P	112105-56-3P
	112105-57-4P	112105-58-5P	112105-59-6P	112105-60-9P
	112105-62-1P	112105-63-2P	112105-64-3P	112105-65-4P
	112105-67-6P	112105-68-7P	112105-69-8P	112105-70-1P
	112105-72-3P	112105-73-4P	112105-74-5P	112105-75-6P
	112105-77-8P	112105-78-9P	112105-79-0P	112105-80-3P
	112105-82-5P	112105-83-6P	112105-84-7P	112135-79-2P
	112245-01-9P	112245-02-0P	112245-03-1P	


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as collagenase inhibitor)

IT **112105-55-2P** **112105-83-6P** **112105-84-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as collagenase inhibitor)

RN 112105-55-2 HCPLUS

CN Glycine, N-[N-[2-[(formylhydroxyamino)methyl]-4-methyl-1-oxopentyl]-L-leucyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 112105-83-6 HCPLUS


CN L-Alanine, N-[N-[2-[(formylhydroxyamino)methyl]-4-methyl-1-oxopentyl]-L-leucyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 112105-84-7 HCAPLUS

CN Pentanamide, 2-[(formylhydroxyamino)methyl]-4-methyl-N-[3-methyl-1-[(methylamino)carbonyl]butyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1985:488204 HCAPLUS

DOCUMENT NUMBER: 103:88204

TITLE: New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties

AUTHOR(S): Fournie-Zaluski, Marie Claude; Coulaud, Annie; Bouboutou, Romaine; Chaillet, Pierre; Devin, Jocelyne; Waksman, Gilles; Costentin, Jean; Roques, Bernard P.

CORPORATE SOURCE: Dep. Chim. Org., U.E.R. Sci. Pharm. Biol., Paris, 75006, Fr.

SOURCE: Journal of Medicinal Chemistry (1985), 28(9), 1158-69
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 103:88204

AB Bidentate ligands (R,S)-HONHCOCH(CH₂Ph)CONHCH₂COR (R = OH, OMe, NHCH₂CH₂CHMe₂, NHCH₂Ph), (R,S)-HCON(OH)CH(CH₂Ph)CONHCH₂COR (R = OH, NHCH₂CH₂CHMe₂), (R,S)-HCON(OH)CH₂CH(CH₂Ph)CONHCH₂COR [R = OH (I), OMe, NHCH₂CH₂CHMe₂, NHCH₂Ph], and (R,S)-HONHCOCH₂CH(CH₂Ph)CO-X-R [X = Gly, R = OH (II), NHCH₂CH₂CHMe₂; X = L-Ala, R = OH (III)] were prepd. as inhibitors of in vitro metab. of enkephalins, ensured by three different metallopeptidases. I, II, and III behave as full inhibitors of the 3 enzymes, with IC₅₀ values in the nanomolar range for enkephalinase, from 0.3 .mu.M to 2 nM for dipeptidylaminopeptidase, and in the micromolar range for a biol. relevant aminopeptidase. Two diastereoisomers of the most active inhibitor III were sep'd. by HPLC and their stereochem. assigned by ¹H NMR spectroscopy. Both isomers were efficient as enkephalinase blockers, but only the RS isomer, designated kelatorphan, was able to strongly inhibit aminopeptidase and dipeptidylaminopeptidase. Intracerebroventricular injection in mice of these mixed inhibitors, esp. kelatorphan, led to naloxone reversible analgesic responses (hot-plate

test) that were slightly better than those produced by a mixt. of thiorphan and bestatin, two potent inhibitors of enkephalinase and aminopeptidase, resp. Kelatorphan was also more efficient in potentiating the analgesia induced by a subanalgesic dose of Met-enkephalin. All these results support a physiol. role in pain transmission for enkephalinase and possibly a synaptic aminopeptidase.

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 7

IT 86962-93-8P 87438-04-8P 87438-06-0P 92175-55-8P 92175-56-9P

92175-57-0P 92175-64-9P 96866-03-4P 96866-04-5P **96866-05-6P**

96896-83-2P 96896-84-3P **96896-85-4P** 96896-86-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and enkephalinase-inhibiting activity of)


96866-05-6P 96896-85-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and enkephalinase-inhibiting activity of)

RN 96866-05-6 HCAPLUS

RN 96896-85-4 HCAPLUS

CN Glycinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1983:558866 HCAPLUS

DOCUMENT NUMBER: 99:158866

TITLE: Amino acid derivatives and their therapeutic use

INVENTOR(S): Roques, Bernard; Schwart, Jean Charles; Lecomte, Jeanne Marie

PATENT ASSIGNEE(S): Fr.

SOURCE: Eur. Pat. Appl., 105 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 82088	A1	19830622	EP 1982-402314	19821216
EP 82088	B1	19860402		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
FR 2518088	A1	19830617	FR 1981-23488	19811216
FR 2518088	B1	19871127		
JP 58150547	A2	19830907	JP 1982-221060	19821216
JP 03046463	B4	19910716		
AT 18902	E	19860415	AT 1982-402314	19821216
US 4618708	A	19861021	US 1985-715764	19850325
US 4738803	A	19880419	US 1986-900814	19860822
PRIORITY APPLN. INFO.:			FR 1981-23488	19811216
			US 1982-449687	19821214

EP 1982-402314	19821216
US 1985-715764	19850325

OTHER SOURCE(S):

CASREACT 99:158866

AB R-X-Y-Z-CHR1COR2 [R = phosphono, sulfo, amino, carbamoyl, alkyl; X = CH(CH₂)nR₃ (n = 0-2; R₃ = H, (un)substituted alkyl, Ph, naphthyl, cyclohexyl, thienyl, etc.), C:CHR₃; Y = CO, NH, CH₂CO; Z = CO, NR₄ (R₄ = alkyl, R₁R₄ = a ring); R₁ = H or (un)substituted alkyl or Ph; R₂ = OH or (un)substituted alkyl, phenoxy, amino, etc.] were prep'd. (101 compds. claimed). Thus, reaction of PhCH₂CHBrCO₂H with PhCH₂ONH₂, followed by formylation and coupling with glycine benzyl ester tosylate gave PhCH₂ON(CHO)CH(CH₂Ph)CO-Gly-OCH₂Ph. The products are useful as enkephalinase inhibitors, analgesics, antidepressants, antidiuretics, and hypotensives. Thus, HON(CHO)CH₂CH(CH₂Ph)CO-Gly-NHCH₂C₆H₄F-p was an effective analgesic, countering the effects of phenylbenzoquinone at 1 mg/kg i.v.

IC C07C103-48; C07C103-50; C07C103-52; C07C103-84; C07C103-76; C07C149-24; C07C147-14; C07D209-20; C07D295-08; C07C145-02; C07C143-53

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 63

IT	76932-18-8P	87428-94-2P	87429-01-4P	87437-85-2P	87437-87-4P
	87437-88-5P	87437-89-6P	87437-90-9P	87437-91-0P	87437-92-1P
	87437-93-2P	87437-95-4P	87437-96-5P	87437-97-6P	87437-99-8P
	87438-01-5P	87438-04-8P	87438-06-0P	87438-11-7P	87438-13-9P
	87438-14-0P	87438-15-1P	87438-18-4P	87438-20-8P	
	87438-22-0P	87438-27-5P	87438-29-7P	87438-31-1P	87438-36-6P
	87438-38-8P	87438-40-2P	87438-42-4P 87438-43-5P		
	87438-44-6P	87438-45-7P	87438-47-9P	87438-49-1P	87438-51-5P
	87438-53-7P	87438-55-9P	87438-60-6P	87438-63-9P	87438-66-2P
	87438-69-5P	87438-72-0P	87438-74-2P	87438-79-7P	87438-88-8P
	87454-28-2P				

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT **87438-41-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(prepn., hydrogenolysis, and biol. activities of)

IT **87438-14-0P 87438-42-4P 87438-43-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 87438-14-0 HCPLUS

CN Glycinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 87438-42-4 HCPLUS

CN L-Tryptophanamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 87438-43-5 HCPLUS

CN L-Alaninamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



IT 87438-41-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prep., hydrogenolysis, and biol. activities of)

RN 87438-41-3 HCPLUS

CN Glycinamide, N-formyl-N-hydroxy-2-(phenylmethyl)-.beta.-alanyl-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

